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ABSTRACT

THE ROLE OF CANNABINOIDS AND CANNABINOID RECEPTORS IN ENTERIC
NEURONAL SURVIVAL
By Yan Li
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University 2009
Major Director: John R. Grider,
Professor, Department of Physiology and Biophysics

The Endocannabinoid system has been found in the gastrointestinal tract, where it plays
an important role in gut under both physiological and pathological conditions. Although
the major effects of cannabinoids in the gut are mediated through effects on enteric
neurons, the role of cannabinoids in the enteric nervous system is poorly understood. In
the present study, we have used the primary cultures of myenteric ganglia and a newly
developed fetal enteric neuronal cell line to identify whether the endocannabinoid,
anandamide, affects ganglionic and neuronal survival and the pathways involved.
Anandamide had a biphasic effect on ganglionic survival, increasing survival at low
concentrations (1nM-0.1uM) and decreasing survival at high concentrations (1-10uM).
Maximal survival (68% increase in number of ganglia surviving) occurred at 0.1uM and
the ED50 was 3nM. This effect on promoting survival was inhibited by the CB1
antagonist AM251 (1uM) and by AraC (10uM), but not the CB2 antagonist AM630
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(1uM). AM630 (1uM) significantly blocked the decreased survival induced by high
concentration anandamide (10uM). The enteric glia was involved in anandamide-induced
ganglion survival. Anandamide had no effect on the number of neurons/ganglion in the
presence of enteric glia, but decreased the number of neurons/ganglion by 15-20% in
absence of enteric glia. This effect was partially reversed by CB1 antagonist, AM251
(1uM) (20%-145% at 1nM-10uM) and by CB2 antagonist AM630 (1uM) (40%-185% at
1nM-10uM). In the fetal enteric neural cell line (IM-FEN), anandamide decreased enteric
neuronal survival in a concentration-dependent manner at both 39 and 33 degree (11-45%
and 10-22%decrease in survival at 1nM-10uM, respectively). Coculture of astrocytes
with the enteric neuronal cells was not able to reverse anandamide-mediated neuronal
death. Immunocytochemistry and western blot confirmed that the presence of both CB1
and CB2 receptors in enteric neurons (primary cultures and IM-FEN) and glia (primary
cultures). In addition, the PLC-beta inhibitor U73122 (1uM) inhibited anandamide
induced ganglia survival significantly. Anandamide also induced increased expression of
phospho-P44/42MAPK (13-48% at 1nM-10uM) and phospho-AKT (1-28% at 1 nM10uM) in IM-FEN.
We conclude that anandamide has a differential effect on survival of enteric ganglia and
neurons. It promotes ganglionic and neuronal survival by CB1 receptors in the presence
of glia and this involves the PLC-beta pathway. Conversely, anandamide promotes
neuron death in absence of glia as a result of effects on both the MAPK and PI-3K/AKT
pathways. Since the endocannabinoid system is upregulated in inflammatory bowel
diseases, these effects may play a role in the pathogenesis of the response to
inflammation as well as the recovery and reinnervation of the gut following the acute
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phase of inflammation. The further significance of this work could contribute to
developing new therapeutic methods for treatment of inflammatory bowel disease and
related symptoms in clinic practice.

Introduction

Enteric nervous system
The gut is innervated by both extrinsic (parasympathetic and sympathetic) and intrinsic
enteric nervous system (ENS). The extrinsic parasympathetic inputs originate in the
dorsal motor nucleus of the vagus, which controls primarily the motility of the esophagus
and stomach, and the sacral parasympathetic nucleus, which contributes to control of
motility of the distal colon and rectum. The sympathetic adrenergic fibers from the
prevertebral ganglia innervate the secretomotor neurons, presynaptic cholinergic nerve
endings, submucosal blood vessels, and the sphincters of the GI tract.
The enteric nervous system consists of the ganglia which are grouped into two plexuses:
the myenteric plexus (Auerbach’s plexus), located between the outer longitudinal and the
inner circular muscle layers, and submucosal plexus (Meissner plexus), located between
the circular muscle and the muscularis mucosa (Figure 1). The myenteric plexus
primarily provides motor innervation to the muscle layers and some secreomotor
innervation to the mucosa. The submucosal plexus mainly regulates mucosal secretion
and blood flow (1).

Enteric neurons
The enteric ganglia consist of enteric neurons and glia. Enteric neurons are classified into
different categories based on their histochemical, electrophysiologic and functional

1

2

Figure 1. Structure of the gut wall. The GI tract can be divided into: mucosa, submucosa,
circular muscle layer, longitudinal muscle layer and serosa from inside to outsider in
order. Myenteric plexus (Auerbach’s plexus) is located between the inner circular muscle
layers and outer longitudinal, and submucosal plexus (Meissner plexus), located between
the circular muscle and the muscularis mucosa. Adapted from John B. Furness136

3

4

properties. They are functionally classified into intrinsic primary afferent neurons
(IPANs), interneurons, motor neurons, secretomotor neurons, and vasomotor neurons.
The IPANs are located in both the myenteric and submucosal plexuses. AH/Dogiel Type
II neurons have smooth oval cell bodies with multiple processes (Dogiel Type II) and
prolonged hyperpolarization after action potential, which have been found in the
myenteric and submucosal plexuses of the small and large intestines. There is
considerable evidence that AH neurons behave as intrinsic sensory neurons as they
respond to a variety of chemical and mechanical stimuli applied to the mucosa and to
muscle stretch and contraction (2-9). Local chemical and mechanical stimulation of the
mucosa activate IPANs in part via release of serotonin from enterochromaffin cells, and
then serotonin activate terminals of IPANs via 5-HT4 receptors (10,11).
The other electrophysiological type of neurons are S/Type I neurons, which have a
variety of cell shapes and are uniaxonal. Fast excitatory postsynaptic potential (FEPSPs)
can be readily evoked in S neurons. S neurons comprise the motor neurons and most of
the interneurons. There are some mechanosensitive interneurons found in the guinea pig
distal colon where they respond directly to changes in muscle length (circumferential
stretch and longitudinal stretch), rather than muscle tone or tension (12).
The peristaltic reflex is a coordination of IPANs, interneurons and excitatory and
inhibitory motoneurons which allows the normal propulsion of the contents of the gut.
The ascending excitatory reflex involves myenteric motor neurons that utilize Ach and
substance P and elicit contraction of the smooth muscle located orally to the site of
stimulation. The descending inhibitory reflex involves inhibitory motor neurons that
utilize NO, VIP and PACAP and elicit relexation of the smooth muscle located anally to
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the site of stimulation (13).

Enteric glia
The most abundant cells in the ENS are enteric glial cells that lie adjacent to the neurons
in the enteric ganglia and envelop both their cell bodies and axon bundles (9). They were
also found in the interconnecting nerve strands of the ganglionated and in all nonganglionated plexuses, submucosal blood vessels and the mucosal epithelium (14-20).
The enteric glia has an important role in regulating barrier function of the intestinal
epithelium (21-22) and neurochemical coding of enteric neurons (23). Proinflammatory
cytokines induced neurotrophic factors glial-derived neurotrophic factor (GDNF) and
nerve growth factor (NGF) expression in enteric glia, suggesting their active role in
inflammation (24-25). Recently, the communication between neuron and glia has been
found in both guinea pig and mice where neuron released ATP could elicit a Ca2+
response in enteric glia (26-27). In addition, lipopolysaccharides (LPS) enhanced the
action of bradykinin in enteric neurons via secretion of interleukin-1β (IL-1β) from
enteric glial cells in neonatal rats (28).

Interstitial cells of Cajal
Interstitial cells of Cajal (ICC) are a non-neural cell type of similar mesenchymal origin
to the muscle, which have been found throughout the gastrointestinal tract from the
esophagus to the anus in a wide variety of species including humans. Morphological and
physiological studies indicate that ICC play key roles in peristaltic movement as
pacemaker cells and as mediators of neural activity to the gastrointestinal musculature
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(29). Each part of the digestive tract shows a specific distribution of ICC.
ICC show a highly branched morphology and form unique networks including myenteric
ICC at the level of the myenteric plexus (ICC-MY), intramuscular ICC in the
musculature (ICC-IM), ICC in deep muscular plexus layer in the small intestine (ICCDMP) and submucosal ICC at the submucosal surface of the circular muscle layer (ICCSM). ICC-MY and ICC-SM serve as electrical pacemakers, generating slow waves,
whereas ICC-IM and ICC-DMP are mediators of enteric motor neurontransmission so
that neural influence is superimposed on the rhythmic activity of the muscle generated by
ICC. ICC are primarily innervated by nitrergic (nNOS-containing) enteric neurons (30).
However, inhibitory neurotransmitters can reach smooth muscle cells without hindrance
when ICC are absent in fundus of stomach (31). In the small intestine, electrical slow
waves are generated by ICC-MY, whereas slow waves in the colon originate in ICC-SM.
The reason could be due to that ICC-SM form a tightly coupled network that is able to
generate and propagate slow waves in the colon; in contrast, Ca2+ transients in ICC-MY
which are normally not synchronized, have a similar duration and frequency as myenteric
potential oscillations (MPOs). Like MPOs, their activity is inhibited by nitrergic nerves
and synchronized by excitatory nerves (32).

Endocannabinoid system
Endocannabinoids
Cannabinoids have a long history of consumption for recreational and medical reasons.
Δ9-tetrahydrocannabinol (Δ9-THC) is the primary active constituent of the hemp plant
Cannabis sativa, which is mediated by at least two types of receptors (CB1 and CB2
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receptors). Both of them are coupled to Gi/o proteins (33,34). The endogenous ligands for
these receptors are also detected in mammalian tissues which are eicosanoids including
arachidonoylethanolamide (anandamide) and 2-arachidonoyl glycerol (2-AG) (35).
Endocannabinoids are generated and released on demand after cellular depolarization in a
calcium-dependent manner (36) or by activating dendritic metabotropic glutamate
receptors (mGluRs) in a calcium-independent manner (37,38).
Different pathways are involved in the synthesis and release of anandamide and 2-AG.
Anandamide is formed by the cleavage of a phosphatidylethanolamine (NAPE), which is
catalysed by a specific phospholipase D (PLD) (39) (Figure2). 2-AG is mainly
synthesized by the receptor-dependent activation of phosphatidylinositol-specific
phospholipase C (PLC) (40,41). Once anandamide and 2-AG are formed, they target the
CB1 receptors in the same cell where they were formed (42) or they can be released to
the presynaptic terminals, acting as the retrograde synaptic messengers (43) in the brain.
Endocannabinoids are removed from their sites of action by tissue uptake processes
which could be involved in endocannabinoid membrane transporter (EMT) and
metabolized mainly by fatty acid amide hydrolase (FAAH) for anandamide or
monoacylglycerol lipase (MAGL) for 2-AG (35).

CB1 and CB2 receptors
CB1 receptors are found predominantly at central and peripheral nerve terminals and
expressed at high levels in the hippocampus, cortex, cerebellum, and basal ganglia (4446). CB2 receptors occur mainly on immune cells, one of their roles being to modulate
cytokine release (47). Recently GPR55, an orphan G protein-coupled receptor,
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Figure 2. A schematic representation of the putative pathway for anandamide
biosynthesis
N-acyl transferase (NAT), using phosphatidylcholine (PC) and phosphatidylethanolamine
(PE) as substrates, transfers a fatty acyl chain from the sn-1 position of a glycerolipid to
PE in a calcium-dependent fashion, yielding N-arachidonyl phosphatidylethanolamine
(NAPE). The formation of anandamide (AEA) is catalyzed by a calcium-dependent
NAPE phospholipase D (NAPE PLD). Adopted from Ekaterina A. Placzek137
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has been proposed as a new member of the cannabinoid receptors (48).
Endocannabinoids exhibit different binding properties and intrinsic activity at CB1 and
CB2 receptors. Anandamide behaves as a partial agonist at both CB1 and CB2 receptors,
but has higher affinity for the CB1 receptor (49,50) .The intrinsic activity of anandamide
at CB1 receptors is 4–30 fold higher than at CB2 receptors. However, 2-AG is a complete
agonist at both CB1 and CB2 receptors and it exhibits less affinity than anandamide for
both CB1 and CB2 receptors (40,49).
Taken together, endocannabinoids, their synthetic and degradative enzymes, eCB
transporters, and cannabinoid receptors constitute the ‘endocannabinoid system’.

Pharmacology of cannabinoids
The mainly used cannabinoid reagents are summarized in Table1 and the structure of
typical cannabinoid agonists shown in Figure3.

Cannabinoid receptor agonists
According to the International Union of Pharmacology, cannabinoid agonists can be
divided into classical cannabinoids, non-classical cannabinoids, aminoalkylindoles and
eicosanoids. Classical cannabinoids are tricyclic dibenzopyran derivatives that are either
compounds occurring naturally in the plant C. sativa, or synthetic analogues of these
compounds. The most representative forms are Δ9-THC, a partial agonist at both the CB1
and CB2 receptors and the main psychoactive constituent of Cannabis, along with 11hydroxy-Δ 8-THC-dimethylheptyl (HU-210), a synthetic compound that displays the
highest potency at the CB1 receptor (49). Non-classical cannabinoids are synthetic THC
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Table 1. The mainly used cannabinoid reagents (35,38)
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Main cannabinoid agonists and antagonists
Ligand
Non-selective cannabinoid receptor agonists
Anadamide
2-AG
HU210
CP55,940
Δ9-THC
R-(+)-WIN-55,212-2

Chemistry
Eicosanoid derivative, endogenous ligand
Eicosanoid derivative, endogenous ligand
Dibenzopyrane derivative, synthetic
Analog of Δ9-THC lacking a pyran ring,
synthetic
Dibenzopyrane derivative, plant-derive
Aminoalkylindole, synthetic

Selective CB1 receptor agonists
ACEA
Noladin ether
R(+)-methanadamide
ACPA
O-1812

Eicosanoid, synthetic
Lipid-ether, endogenous ligand
Eicosanoid, synthetic
Eicosanoid, synthetic
Eicosanoid, synthetic

Selective CB2 receptor agonists
JWH-015
JWH-133
L-759633
L-759656

Aminoalkylindole, synthetic
Analog of Δ9-THC, synthetic
Analog of Δ9-THC, synthetic
Analog of Δ9-THC, synthetic

Selective CB1 receptor antagonists
SR141716A
AM281
SR147778
LY320135
LH-21
AM251

Diarylpyrazole, synthetic
Diarylpyrazole, synthetic
Diarylpyrazole, synthetic
Substituted benzofuranes, synthetic
Triazole derivatives, synthetic
Diarylpyrazole, synthetic

Selective CB2 receptor antagonists
SR144528
AM630

Diarylpyrazole, synthetic
Aminoalkylindoles, synthetic

Uptake inhibitors
AM404
UCM707
AM1172

Eicosanoid derivatives, synthetic
Eicosanoid derivatives, synthetic
Eicosanoid derivatives, synthetic

FAAH inhibitors
OL-135
URB597
PIA

Alpha heterocycles, syntheric
O-arylcarbamate, synthetic
Eicosanoid derivatives, synthetic
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Figure 3. The structure of typical cannabinoid agonists (191).
Δ9-THC is a tricyclic dibenzopyran derivatives from plant Cannabis. CP-55940 is a
synthetic THC analogue that lack the dihydropyran ring. R-(+)-WIN-55,212–2 is the
represent form of aminoalkylindoles. Endocannabinoids anandamide and 2-AG are
eicosanoids.

14

15

analogues that lack the dihydropyran ring. The most representative form is the Pfizer
compound CP-55940, a potent and complete agonist at both the CB1 and CB2 receptors,
which was used to characterize the CB1 receptor for the first time (44,51).
Aminoalkylindoles

were

the

first

non-cannabinoid

molecules

that

displayed

cannabimimetic activity (52). R-(+)-WIN-55,212–2 is the most representative form, and it
behaves as a complete agonist at both the CB1 and CB2 receptors, with higher intrinsic
activity at the CB2 receptor. Eicosanoids are the prototypic endocannabinoids, of which
anandamide and 2-AG are the most representative compounds. Based on the structure of
anandamide, minor chemical changes have led to the development of the first generation
of CB1-selective agonists, of which R(+)- methanandamide and arachidonyl-2’chloroethylamide (ACEA) are the most representative forms (50).

Cannabinoid receptor antagonists
Several compounds have been developed as cannabinoid receptor antagonists such as
diarylpyrazoles, substituted benzofuranes, aminoalkylindoles and triazole derivatives
(53). Diarylpyrazoles include both the first CB1 receptor antagonist SR 141716A (54)
and the first CB2 receptor antagonist SR 144528. A CB2 receptor antagonist, AM 630,
belong to aminoalkylindoles (49).

Uptake blockers and inhibitors of fatty acid amide hydrolase
Based on the structure of anandamide, a series of eicosanoid derivatives that have the
ability to block anandamide transport have been synthesized (53). The first and best
studied transport inhibitor is AM 404 (55). The administration of AM 404 results in the
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accumulation of anandamide and potentiates the effects of exogenously administered
anandamide. The compound AM 404 can be degraded by FAAH and behaves as an
agonist of vanilloid receptors. UCM 707 (56,57) and AM 1172 (58) have also been
shown to efficiently block endocannabinoid uptake. In addition, OL-135 has been shown
to possess very high potency and selectivity to reversibly inhibit FAAH activity in vivo
and in vitro (59).

Endocannabinoid signaling
CB1 signaling transduction pathways
The CB1 cannabinoid receptor is a member of the rhodopsin subfamily of GPCRs, which
is coupled through Gi/o proteins, negatively to adenylate cyclase and positively to
mitogen-activated protein kinase. CB1 receptor stimulation is also coupled to PLC
activation, in turn increasing levels of InsP3 for the induction of Ca2+ release from
internal stores (60). CB1 receptors can also interact with Gs to activate adenylate cyclase
under conditions of PTX treatment that prevents the receptor interaction with Gi/o
proteins (61,62) and in human embryonic kidney (HEK) 293 cells transfected with CB1
and D2 receptors (63).
In addition, CB1 receptors are coupled through Gi/o proteins to certain ion channels,
activating G-protein-coupled inward rectifier K+ (64) and A-type outward potassium
channels (65), and inhibiting D-type outward potassium channels (66), N-type and P/Q
type calcium channels (67,68), L-type Ca2+ currents (69). Regardless of the specific
target, the actions of cannabinoids are predicted to have an inhibitory effect on neurons in
most cases. Inhibition of presynaptic calcium channels reduces neurotransmitter release,
whereas activation of postsynaptic K+ channels suppresses action-potential firing (70).
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CB2 signaling transduction pathways
Similar to CB1, CB2 receptors activation can inhibit adenylyl cyclase (71,72) and
activate p42/p44 MAP kinase activity, through their ability to couple to Gi/o proteins in
CHO cells and HL-60 cells (73,74). Treatment of human prostate epithelial PC-3 cells
with cannabinoids activated the PI3K/PKB pathway, which in turn induced translocation
of Raf-1 to the membrane and phosphorylation of p42/p44 MAP kinase through CB2
receptor (75). In addition, anandamide could initiate a rise in [Ca2+]i in calf pulmonary
endothelial cells through activation of PLC , which was sensitive to inhibition by the CB2
antagonist (76), suggesting CB2 receptor was involved in this process.
However, in contrast to CB1, CB2 receptor stimulation was not found to modulate ion
channel function in AtT-20 cells transfected with CB2 (77) and Xenopus oocytes
transfected with CB2 and GIRK1/4 (78).

Cannabinoids in gut
Cannabinoid receptors in gastrointestinal tract
The presence of cannabinoid receptors in the gastrointestinal tract has been demonstrated
by anatomical and functional evidences, which was summarized in table 2.
CB1 receptors were detected in enteric nervous system of different species, including
mice, rats, guinea pigs, pigs and humans by immunohistochemistry (79-88), where it is
frequently colocalized to ChAT neurons. Interestingly, they were not coexpressed in
NOS-positive neurons in pig and mice (79,84,85).
CB2 receptor expression was present on plasma cells in the lamina propria and
macrophages in human colon (88). Later it was detected in enteric neurons
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Table 2. Localization of cannabinoid CB1 and CB2 receptors in the gastrointestinal tract.
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Localization of cannabinoid CB1 and CB2 receptors in the gastrointestinal tract.
Animal
Region of the gut
Technique
Findings
species
Pig (22)
Ileum
IHC
All CB1 colocalized with ChAT
CB1 occasionally associated with SP
CB1 co-localised with opioid receptor
CB1 not with VIP or NOS-positive neurons
Colon
IHC
Most CB1 colocalized with ChAT
CB1/ChAT-neurones frequently expressed SP in
submucosal plexuses
CB1 not with VIP or NOS-positive neurons
Guinea
Myenteric plexus
IHC
Sensory, interneuronal and motoneuronal cell
pig (21)
bodies and nerve fibres expressed CB1
Guinea
Submucosal plexus
IHC
CB1 colocalized with VIP and NPY
CB1 colocalized with TRPV1 on paravascular
pig (37)
of ileum
nerves and fibers in the submucosal plexus
Rat (33)
Stomach fundus,
IHC
CB1 colocalized with CHAT in neural elements
corpus and antrum.
innervating smooth muscle, mucosa and
submucosal blood vessels
CB2 not observed
Rat (21)
Whole mounts of
IHC
CB1 expressed on cholinergic sensory,
myenteric
interneuronal, and motor neurons
preparations
All regions
Immunoblotting
CB1 high in stomach and colon, but not in the
Mice (24)
pyloric valve
IHC
CB1 in ganglia subadjacent to the gastric
epithelium and in the smooth muscle layers of
both the small and large intestine.
Radioligand
[3H]CP 55,940 specific binding in the small
binding
intestine
Mice
Colon
IHC
CB1 in neurons within myenteric and
(31,32)
submucosal ganglia and nerve fibers
CB1 frequently colocalized to a subpopulation
of CHAT neurons and fiber bundles in the
myenteric plexus
CB1-R and NOS not overlap in myenteric or
submucosal neurons and fibers
Human
Stomach and colon
RT-PCR
CB1 mRNA detected
(38)

Human

Colon

IHC

Human

Colon

IHC

(39)

(40)

CB1 in all major ganglionated nerve plexuses,
predominantly within myenteric ganglia.
CB1 in the submucosal plexus, mucosa and in
serosa
CB1 coexpressed with CHAT in myenteric
neurones
CB1-R/ChAT nerve fibers in CM layer and
submucosa
CB1 evident in epithelium, smooth muscle, and
the submucosal myenteric plexus
CB1 on plasma cells in the lamina propria
CB2 on plasma cells in the lamina propria and
macrophages
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morphologically and functionally (89). In addition, CB2R has been demonstrated to
reside on a wide variety of peripheral blood leukocytes and spleen cell populations (90)
and to a greater extent than seen for CB1R in the same cell types that include B cells, T
cells, NK cells, splenic macrophages, dendritic cells, and neutrophils (91-93).

Physiological role of cannabinoids and CB receptors in GI
Activation of CB1 receptor has been reported to inhibit pentagastrin-induced gastric acid
secretion (82,94) at peripheral level. I.c.v. injection of anandamide stimulated gastric acid
secretion, however, the response was inhibited by an antagonist of TRPV1 and in the
capsaicin-treated rats, but not by an antagonist of cannabinoid receptors (95). It suggested
that anandamide could activate TRPV1 in the brain and stimulates gastric acid secretion
in rats.
Generally cannabinoids mediate an inhibitory effect on GI motility. Functional studies
have shown that cannabinoids inhibited (via CB1 activation) lower oesophageal sphincter
relaxation in dogs (96) and ferrets (97) which could be mediated by modulation of vagal
activity at peripheral and central levels. Intravenous Δ9-THC administration slows down
the rate of gastric emptying of solid food in humans (98). In addition, several cannabinoid
agonists inhibited gastric and intestinal motility in rats and mice through CB1 activation
(99-101). The antipropulsive effects of cannabinoids could be the result of inhibition of
both excitatory cholinergic/tachykininergic and inhibitory VIPergic motor neurons which
mediate ascending contraction and descending relaxation respectively, as well as
inhibition of the intrinsic sensory CGRP-containing neurons which initiate the peristaltic
reflex underlying propulsive activity (102).
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Pathological role of cannabinoids and CB receptors in GI (Summarized in table 3)
Inflammation
Inflammation represents the response of body tissue to immune reactions, injury, or
ischemic damage (103). It can be divided into two basic patterns: acute and chronic
(104,105). Acute inflammation is of relatively short duration, lasting from a few minutes
to several days, and is characterized by the exudation of fluid and plasma components
and emigration of leukocytes, predominantly neutrophils, into the extravascular tissues.
Chronic inflammation is of a longer duration, lasting for days to years, and is associated
with the presence of lymphocytes and macrophages, proliferation of blood vessels,
fibrosis, and tissue necrosis (103).
Acute inflammation is the early (almost immediate) reaction of local tissue and their
blood vessels to injury. It typically occurs before the immune response becomes
established and is aimed primarily at removing the injurious agent and limiting the extent
of tissue damage. Acute inflammation involves two major components: the vascular and
cellular stages (104-106). The vascular, or hemodynamic, changes are initiated by a
momentary constriction of small blood vessels in that area, which is followed rapidly by
vasodilatation of the arterioles and venules that supply the area. Accompanying this
response is an increased permeability of vessels in the microcirculation, with the
outpouring of a protein-rich fluid (exudate) into the extravascular spaces. The cellular
stage of acute inflammation is marked by movement of leukocytes into the area of injury.
Two types of leukocytes participate in the acute inflammatory response-granulocytes and
monocytes (103).
A rapid response also requires the release of chemical mediators from tissue cells (mast
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Table 3. The role of cannabinoids and cannabinoid receptors in inflammation of
gastrointestinal tract.
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The role of cannabinoids and cannabinoid receptors in inflammation of gastrointestinal tract
Experimental models /animal
Functions
species
Ileum
Rat (63)
Anandamide and 2-AG caused ileitis via VR1 and SP release
WIN 55,212-2, HU 210 and PEA had no affect
Indomethacin-induced small
Oral CB1 antagonist prevented ulcers and the rise in TNF-α levels
intestinal injury (rat) (66)
and intestinal MPO activity.
Oral CB2 antagonist prevented intestinal ulcers only
(+)-WIN 55, 212-2 and CP 55940 had no effects
(66)
LPS-induced ileitis (rat)
Oral CB1 antagonist prevented the increase of TNF-a levels
CB2 antagonist had no effect
LPS-induced ileitis (WT and CB1- Oral CB1 antagonist inhibited the increase of TNF-a in WT, but not
/- mice) (66)
in CB1-/- mice
CB2 antagonist had no effect in both WT and CB1-/- mice
Croton oil-induced intestinal
Cannabinoids (i.p.) were more active in delaying intestinal motility
inflammation (mice) (68)
via peripheral CB1 receptors
LPS-induced ileitis (rat) (70)
CB2 agonist inhibits intestinal motility via cyclooxygenase, IL-1β
and eNOS.
Colon
Intracolonic OM induced acute
CB1 and CB2 agonists (i.p.) attenuate OM colitis
CB1R upregulated in endothelium and myenteric ganglia
colitis (mice) (75)
CB2R-positive cells were evident
(75)
DSS induced colitis (mice)
CB1 and CB2 agonists attenuated DSS colitis
CB1R upregulated in myenteric ganglia
CB2R immunoreactivity evident
DNBS and DSS colitis (WT and
DNBS and DSS induced stronger inflammation in CB1-/- mice
Cannabinoid agonist HU210 or FAAH-/- protect against DNBS
CB1-/- mice) (77)
colitis
Myenteric neurons expressing CB1 increased in DNBS colitis
DNBS colitis (CB1−/−, TRPV1−/− Rhythmic action potentials in colonic circular smooth muscle cells
and WT mice) (78)
of CB1−/− and TRPV1−/− mice
IJP in CB1−/− mice was longer
DNBS colitis (mice)
TNBS colitis (rat)
Ulcerative colitis (human) (81)
TNBS colitis (rat) (82)

Rats and mice (83)
Butyrate enemas elicited colonic
hypersensitivity (rat) (83)
Human colonic epithelial cell lines
(40)

Inflammatory bowel disease
(human) (40)

Elevation of anandamide
Inhibitor of anandamide reuptake (VDM11) abolished
inflammation
Inhibitor of FAAH (AA-5-HT) less efficacious at attenuating colitis
CB1 and CB2 agonists (i.p.) reduce basal sensitivity and TNBS
colitis-induced hypersensitivity to CRD
CB1 antagonist enhanced colitis-induced hyperalgesia.
probiotic bacteria NCFM induced the expression of MOR1 (mopioid receptors) and CB2 in epithelial cells of colonic section
NCFM-induced analgesia was inhibited by CB2-selective
antagonist
Cannabinoids enhanced epithelial wound closure by the CB1
receptor
CB2 immunoreactivity in the epithelium of colonic tissue
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cells and macrophages) that are prepositioned in the tissue (107). Mast cells are
particularly prevalent along mucosal surface of the lung and gastrointestinal tract and the
dermis of the skin. This distribution places the mast cell in a sentinel position between
environmental antigens and the host for a variety of acute and chronic inflammation
conditions (105).
Although inflammation is precipitated by injury, its signs and symptoms are produced by
chemical mediators that are derived either from the plasma or from cells. Plasma-derived
mediators of inflammation include the kinins, the products of the coagulation/fibrinolysis
system, and the proteins of the complement system. Cell-derived mediators include
histamine and serotonin, arachidonic acid metabolites, platelet-activating factors,
cytokines, and nitric oxide (103).
Characteristic of chronic inflammation is an infiltration by mononuclear cells
(macrophages) and lymphocytes instead of the neutrophils commonly seen in acute
inflammation. Chronic inflammation also involves the proliferation of fibroblasts instead
of exudates (103).

Role in ileum inflammation (Figure 4)
Cannabinoids in gut inflammation have been widely studied in experimental animal
models. Endocannabinoids cause inflammation in the rat ileum via capsaicin VR1
receptor-mediated SP release from primary sensory nerves in the intestinal mucosa.
Toxin A increased tissue concentrations of anandamide and 2-AG in the ileum, and these
effects were enhanced after pretreatment with inhibitors of fatty acid amide hydrolase,
suggesting endocannabinoids may mediate the inflammatory effects of toxin A (108).
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Figure 4. Role of cannabinoids and cannabinoid receptors in ileitis.
Continuous arrows denote stimulation and induction. Broken arrows denote inhibition.
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Figure 4. Roles of cannabinoids and cannabinoid receptors in ileitis.
Continuous arrows denote stimulation and induction. Broken arrows denote inhibition.
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Substantial studies have shown that cannabinoid antagonists play a protective role in
inhibition of mucosa damage via both CB1 and CB2 receptors. CB1 antagonists dosedependently prevented indomethacin-induced ulcers, the rise in TNF-α levels and
intestinal MPO activity. CB2 antagonists prevented intestinal ulcers only. In addition,
CB1 antagonists prevented LPS-induced increase of TNF-α levels in rat and wide-type
mice plasma, but not in CB1 receptor knockout mice (109), suggesting that the antiinflammatory role of CB1 antagonists was mainly mediated by cytokine TNF-α.
Cannabinoids (i.p.) were more active in delaying intestinal motility in croton oil-treated
mice than in control mice which was reversed by CB1 antagonist, indicating an
involvement of CB1. Croton oil-induced intestinal inflammation was associated with an
increased expression of CB1 receptor. This up-regulation explains the increased potency
of exogenous cannabinoid agonists during inflammation (110). CB2 receptor agonist
reduced lipopolysaccharide (LPS) stimulated gastrointestinal transit back to control
values, and this inhibition was completely prevented by the CB2 receptor antagonist,
which itself was without effect. The effects of the CB2 agonist were found to act via
cyclooxygenase in that inhibition of cyclooxygenase with indomethacin completely
abrogated the inhibitory effect of CB2 agonist. In addition, IL-1βand constitutive NOS
isoforms (probably eNOS) may be involved in this effect (111).
In summary, cannabinoids may participate in mucosa damage but delay motility in
intestinal inflammation via both CB1 and CB2 receptors.

Role in colitis (Figure 5)
The evidence supported that cannabinoids mediate a protective role in experimental
colitis via both CB1 and CB2 receptors. For example, studies have shown that
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intraperitoneal application of the CB1R-selective agonist ACEA and the CB2R-selective
agonist JWH-133 inhibited Oil of mustard (OM)- and dextran sulfate sodium (DSS)induced colitis (112). Inhibitors of anandamide reuptake (VDM11) significantly elevated
anandamide levels in the colon of DNBS-treated mice and concomitantly abolished
inflammation (113). In addition, both intrarectal infusion of 2,4-dinitrobenzene sulfonic
acid (DNBS) and oral administration of dextrane sulfate sodium (DSS) induced stronger
inflammation in CB1-deficient mice (CB1–/–) than in wild-type littermates (CB1+/+),
and treatment of wild-type mice with the CB1 antagonist mimicked the phenotype of
CB1–/– mice, indicating a protective role of the CB1 receptors during inflammation.
Consistently, treatment with the cannabinoid receptor agonist HU210 or genetic ablation
of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) resulted in
protection against DNBS-induced colitis (114). In addition, cannabinoids enhanced
epithelial wound closure in human colonic epithelial cell lines by the CB1 receptor (88).
During colitis, the endocannabinoid system was also upregulated. Studies showed that the
upregulation of CB1 in endothelium and myenteric ganglia, and also CB2R-positive cells
were evident as a dense, intensely stained infiltrate in OM and DSS colitis tissue (85).
DNBS treatment also increased the percentage of myenteric neurons expressing CB1
receptors (114). CB2 immunoreactivity was seen in the epithelium of colonic tissue
characteristic of inflammatory bowel disease (88). A strong elevation of anandamide, but
not 2-AG, levels was found in the colon of DNBS-treated mice, in the colon submucosa
of TNBS-treated rats, and in the biopsies of patients with ulcerative colitis, suggesting the
protective role of anandamide in colitis and IBDs (113).
In addition, activation of CB1 and CB2 receptors could play an analgesic role in colon
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Figure 5. Roles of Cannabinoids and cannabinoid receptors in colitis.
Continuous arrows denote stimulation and induction. Broken arrows denote inhibition.
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Figure 5. Roles of Cannabinoids and cannabinoid receptors in colitis.
Continuous arrows denote stimulation and induction. Broken arrows denote inhibition.
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inflammation. Studies found that activation of either CB1 or CB2 receptors reduces the
basal sensitivity and the TNBS colitis-induced hypersensitivity to colorectal distension
(CRD) in rats, both agonists being more active in the presence of colitis. These effects
were blocked by their antagonists respectively. CB1 receptor antagonist enhanced colitisinduced hyperalgesia, suggesting the endogenous cannabinoid system is involved in the
inflammatory hyperalgesia through CB1 receptors (115). In a model of chronic colonic
hypersensitivity, elicited by butyrate enemas and mimicking irritable bowel syndrome,
treatment with probiotic bacteria NCFM significantly increased the colorectal distension
threshold which was inhibited by CB2-selective antagonist; in addition, administration of
NCFM significantly induced the expression of CB2 in epithelial cells of colonic section
of rats and mice, providing indirect evidence for a physiological role of CB2 in the
control of intestinal pain (116).
In summary, cannabinoids play a protective role in inflammatory damage and analgesic
role in colitis via both CB1 and CB2 receptors.

Cannabinoids in central nervous system
The role of cannabinoids in the brain has been well studied. Cannabinoids suppressed
neuronal activity via CB1 presynaptic inhibition of neurotransmitters release in
hippocampal and cerebellar neurons (117-123). In addition, endocannabinoids were
involved in regulation of food intake (124), inhibition of emesis (125) and analgesia
(126,127).
The effect of cannabinoids on neuronal survival has been studied by many groups,
however, the results are controversial varying from neuroprotection (128-132) to
neurotoxity (133-135). For example, cannabinoids mediate a neuroprotective effects in
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neurotoxin S-AMPA induced primary cortical neurons death (131). Moreover, the
endocannabinoid system is highly activated during CNS inflammation and anandamide
protects neurons from inflammatory damage via CB1/2 receptors (130). In contrast,
anandamide was also found to induce cell death in primary neuronal cultures via calpain
and caspase pathways (134). Δ9-THC induced apoptosis in cultured rat cortical neurons
via P53 (135).

Hypothesis
Although the major effects of cannabinoids in the gut are mediated through effects on
enteric neurons, the role of cannabinoids in enteric nervous system is poorly understood.
Given the importance of cannabinoids in inflammation of gut and their effects in neuronal
survival and death in CNS, we hypothesize that cannabinoids could affect enteric
neuronal survival and we will identify the pathways involved. Since the endocannabinoid
system is upregulated in inflammatory bowel diseases, this effect may play a role in the
pathogenesis of the response to inflammation as well as the recovery and reinnervation of
the gut following the acute phase of inflammation. The further significance of this work
could contribute to developing new therapeutic methods for inflammatory bowel disease
and related symptoms in clinic practice.

Materials and Methods
Materials
Materials for cell culture
Hartley guinea pigs (150-200g, male) were purchased from Charles River Laboratories
(Wilmington, MA). All procedures with animals were approved by the Institutional
Animal Care and Use Committee at Virginia Commonwealth University.
Dulbecco Modified Eagle’s Medium (DMEM) was purchased from Invitrogen
(Frederick, MD). 10% fetal bovine serum (FBS) was purchased from Atlas (Tartu,
Estonia). The fetal enteric neuronal cell line was a kind gift from Dr. Srinivasan’s group
(University of Emory). DMEM-F12, N2 medium, Neurobasal A medium, B-27 serumfree supplement, 0.25% Trypsin-EDTA were purchased from Invitrogen (Frederick,
MA). rhGDNF was purchased from Promega (Madison, WI). C8-D1A (Astrocyte type I
clone) was purchased from ATCC (Manassas, VA).

Antibodies
Monoclonal to PGP9.5 (Mouse) was purchased from Abcam Inc. (Cambridge, MA). CB1
(N-15) (Goat) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Anti-protein gene product 9.5 (PGP9.5) (Rabbit), anti-S-100 protein monoclonal antibody
(Mouse) and anti-cannabinoid receptor 2, N-terminus (Rabbit) were purchased from
Millipore (Billerica, MA). Alexa Fluor 488 (donkey anti-mouse) and Alexa Fluor 594
(donkey anti-goat, donkey anti-guinea pig and donkey anti-rabbit) are purchased from
Invitrogen (Frederick, MA).
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (rabbit) and p44/42 MAPK
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(Erk1/2) antibody (rabbit) were purchased from Cell signaling (Danvers, MA).
Monoclonal anti-β-actin (mouse, 1:10000) was purchased from Sigma (St. Louis, MO).
Anti-CB1 antibody (rabbit) was purchased from Affinity Bioreagents (Golden, CO). HRP
conjugated 2nd antibodies: goat anti-rabbit (1:1000) and goat anti-mouse (1:1000) and
Supersignal west femto chemiluminescent substrate were purchased from Pierce
(Rockford, IL). Odyssey 2nd antibodies: rabbit (1:10000) and mouse (1:10000) were
purchased from Licor Biosciences (Lincoln, NE).

Other chemicals
Vectastain elite ABC kit (rabbit IgG) and Peroxidase substrate 3, 3’ Diaminobenzidine
(DAB) kit were purchased from Vector Laboratories, Inc. (Burlingame, CA). Protease
inhibitor cocktail was purchased from BD Biosciences (Palo Alto, CA). Protein assay kit
was purchased from Biorad (Hercules, CA). AM251, AM630, Capsazepine, MAP kinase
kinase (MEK) inhibitor PD98059, Phospholipase C (PLC) inhibitor U73122,
Phosphatidylinositol-3-kinase (PI-3K) inhibitor LY 294002 and other chemicals were
purchased from Sigma (St. Louis, MO).

Methods
Collection of tissue
Guinea pigs were sacrificed by CO2 asphyxiation. The small intestine was dissected out
immediately and placed in 37ºC oxygenated Krebs solution of the following composition:
NaCl 118 mM, KCl 4.75 mM, KH2PO4 1.19 mM, MgSO4 1.2 mM, CaCl2 2.54 mM,
NaHCO3 25 mM and Dextrose 11 mM (pH 7.4).
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Preparations of ganglia from guinea pig myenteric plexus
The tissue was cut into 3-4 cm sections for preparation of myenteric ganglia by the
method of Yau (138). The segments of intestine were placed on glass rods and the sheets
of longitudinal muscle with the myenteric plexus were scrapped with a wet Kim wipe and
incubated for 6 minutes at 37ºC in Krebs-bicarbonate solution containing 0.1% protease,
0.2% collagenase type IV and 0.1% BSA for enzymatic digestion. The tissue was
consistently bubbled with 95%O2/5%CO2, accompanied by frequently suctioning with 5
ml pipette to free the ganglia from the smooth muscle cells during this process. The partly
digested tissue was then collected by filtering through 500-um Nitex mesh and incubated
for one hour at 37ºC in enzyme-free Krebs solution bubbling with 95%O2/5%CO2 for
further isolation. The suspension was then filtered to remove the undigested tissue and
the filtrate was centrifuged for 1 minute at 1000 RPM. The supernatant containing
smooth muscle cells and debris was discarded, and the pellet containing the ganglia was
resuspended and washed twice in enzyme-free Krebs solution to remove cell debris. Then
the pellet was resuspended and placed in a 10cm plastic culture dish and the ganglia were
harvested by suction into 20ul capillary tube under dissecting microscope.

Cultures in plates for treatment with anandamide and other reagents
Ganglia were placed in 24 well plates with a density of 15 ganglia per well, and incubated
for three days in Dulbecco Modified Eagle’s Medium (DMEM) containing 200U/ml
penicillin, 200ug/ml streptomycin, 100ug/ml gentamycin, 2.5 ug/ml amphotericin B and
10% fetal bovine serum (DMEM10) at 37ºC 10%CO2 incubator. In some experiments,
the ganglia were incubated in DMEM10 containing 10uM of mitotic inhibitor arabinoside
cytosine (araC) to reduce the glial and other nonneural cell effects on the neurons. After
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three days incubation, the ganglia attached to the bottom of the plates. The wells were
washed two times with serum free medium (DMEM0) containing 200U/ml penicillin,
200ug/ml streptomycin, 2.5ug/ml amphotericin B, and 100ug/ml gentamycin and treated
with anandamide (1nM-10uM) and/or the CB1 antagonist AM251 (1uM) or CB2
antagonist AM630 (1uM) or TRPV1 antagonist capsazepine (1uM) in serum free medium
DMEM0 or DMEM0 with 10uM araC for four days. In one set of experiments, the
ganglia were treated with 0.1uM anandamide and/or MAP kinase kinase (MEK) inhibitor
PD98059

(1uM)

or

phospholipase

C

(PLC)

inhibitor

U73122

(1uM)

or

phosphatidylinositol-3-kinase (PI-3K) inhibitor LY 294002 (1uM). Untreated wells were
taken as a control. Duplicates were done for each treatment in each animal. The plates
were then prepared for immunohistochemistry.

Immunohistochemistry
The plates were washed three times with phosphate buffer saline (PBS) solution
containing 137mM NaCl, 2.682 mM KCl, 3.895 mM Na2HPO4 and 1.764mM KH2PO4 at
4 ºC, and fixed with 4% paraformaldehyde with the following composition: 0.04g/ml
paraformaldehyde, 2.5mM NaOH, 28mM NaH2PO4 and 37.4mM Na2HPO4 for 30
minutes. The cells were then washed twice with PBS, and incubated with 0.1% triton X100 for 10 minutes. After blocking with normal goat serum (NGS) from VECTASTAIN
ABC kit (Vector Laboratories) for 20 minutes, the plates were incubated with primary
antibody to protein gene product 9.5 (anti-PGP9.5) (rabbit, Millipore Corp.) diluted
1:1000 in PBS containing 1% blocking serum at 4 ºC for 24 hours.
On the second day, the cultures were washed three times with PBS and incubated with the
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biotinylated secondary antibody (goat anti-rabbit) for 30 minutes. After washing with
PBS for 5 minutes, wells were incubated with the conjugate of Avidin/Biotinylated
horseradish peroxidase (HRP) complex (VECTASTAIN ABC kit, Vector Laboratories)
for 30 minutes. Then washing once with PBS for 5 minutes, the ganglia were incubated
with 3, 3’-Diaminodenzidine (DAB) working solution from DAB kit (Vector Laboratories,
Inc.) for 4-10 minutes. After washing with distilled water for 5 minutes, the wells were
coved with Crystal/Mount (Biomeda Corp.) and placed at 70 ºC for 10 minutes to dry.
These plates were examined under an inverted light microscope.

Counting of neurons and ganglia and calculations
After staining with the neuronal marker anti-PGP9.5 antibody, the number of ganglia in
each well and the number of neurons in each ganglion were counted. The total number of
neurons was calculated by adding the number of neurons in each ganglion together in
each well. The percentage changes were calculated through the control divided by the
treated groups. The survivals were expressed as the mean of percentage change from
control ±standard error of the mean (SEM).

Cultures for immunofluoresence staining
In this protocol, ganglia were placed in 8 well slides with a density of 15 ganglia per well,
and incubated in DMEM10 medium for seven days at 37ºC 10%CO2 incubator. The
medium was replaced on day 3. Then the ganglia were prepared for immunofluoresence
staining.
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Immunofluoresence staining
After culture of ganglia on 8 well slides for seven days, the slides were washed three
times with IHC solution containing 26mM NaH2PO4 and 39mM Na2HPO4 and fixed with
4% paraformaldehyde as described above for 30 minutes. After washing two times with
IHC solution, the ganglia were treated with 0.3% Triton X-100 for 10 minutes to
permeabilized the cells and incubated for 20 minutes with 3% donkey normal serum
(DNS) to block the nonspecific binding of the antibody. The cultures were then incubated
with the primary antibodies to PGP9.5 (mouse, Abcam) (1:500), S-100 (mouse,
Chemicon) (1:100), CB1 (goat, Santa cruz) (1:100), and CB2 (rabbit, Millipore) (1:100)
at 4 ºC for 24 hours. All primary antibodies were diluted with 3% DNS to inhibit the
nonspecific binding. Negative controls were performed by deleting the primary
antibodies.
On the second day, the slides were washed three times with IHC and incubated two hours
in dark place at room temperature with the secondary antibodies conjugated to either
Alexa Fluor 488 (1:500) or Alexa Fluo 594 (1:500). The secondary antibodies were
determined according to the species of the primary. After incubation, the slides were
washed three times with IHC solution, covered with permaflour, covered with a glass
coverslip, and placed in the dark place for 24 hours to dry. Then slides were sealed with
nail polish and examined under the microscope with appropriate filters for Alexa Fluor
488 or Alexa Fluor 594.

Cultures for enteric neuronal cell line
The enteric neuronal cell line was cultured by the method of Anitha et al (139). The
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frozen cells were thawed at 37ºC for 2-3 minutes, suspended in 10ml N2 medium with
the following composition: DMEM-F12 medium, N2 medium, 10ng/ml GDNF, 10% FBS,
200U/ml penicillin and 200ug/ml streptomycin and centrifuged for 5 min at 130 x g to
remove DMSO. The cells were then resuspended in N2 medium and placed onto T-25
flasks. The flasks were cultured in a humidified incubator containing 10%CO2 at
permissive temperature 33 ºC for proliferation until confluence was attained. The cells in
flask were then dislodged mechanically by trypsin-ethylenediaminetetraacetic acid
(0.25%) and re-plated on 8 well slides and/or 6 well plates at a concentration of 5 X 105
cells/ml in N2 medium. The cells were then incubated for the following protocols. All
experiments were performed between passages 13 and 40 and duplicates were done for
each treatment in each experiment.
Non-treated wells for immunofluoresence staining
The 8 well slides were cultured at 33 ºC for 2-3 days, and then move to 5% CO2 39 ºC
incubator in neurobasal-A medium containing B-27 serum-free supplement, 1mmol/L
glutamine, 5uM Na3VO4, 200U/ml penicillin and 200ug/ml streptomycin for 7 days. The
medium was replaced once on day 3. Then the slides were prepared for
immunofluoresence staining with anti-PGP9.5 (rabbit, 1:1000), anti-CB1 (goat, 1:50) or
anti-CB2 (rabbit, 1:200) antibodies as described above.
Treatment with anandamide at 39 degree for 7 days.
The 8 well slides and 6 well plates were cultured at 33 ºC for 2-3 days, and then treated
with anandamide (0, 1nM, 0.1uM, 10uM) diluted in neurobasal-A medium for 7 days at
5% CO2 39 ºC incubator. The medium was replaced once on day 3. The slides were then
immunostained with anti-PGP9.5 antibody (rabbit, Millipore) as described above. The
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cells grown in plates were prepared for western blot.
Treatment with anandamide at 33 degree for 2 days.
To eliminate the effect of anandamide on cell differentiation at 39 degree, the slides were
cultured at 33 ºC in N2 medium for 24 hours. After this incubation the cells were settled
to the bottom of the slides. The slides were then treated with anandamide (0, 1nM, 0.1uM,
10uM) diluted in N2 medium and continued to incubate at 33 ºC for 2 days. The medium
of slides was changed to neurobasal-A medium without anandamide and cultured for 7
days at 5% CO2 39 ºC incubator. The slides were then immunostained with anti-PGP9.5
antibody (rabbit, Millipore) as described above and examined under microscope.

Coculture of astrocyte cell line with enteric neuronal cell line and treatment with
anandamide.
The astrocyte cell line was thawed in 37ºC for 2-3 minutes, transferred to 75cm2 tissue
culture flasks and diluted in DMEM containing 200U/ml penicillin, 200ug/ml
streptomycin, 100ug/ml gentamycin, 2.5ug/ml amphotericin B and 10% fetal bovine
serum (DMEM10). The flasks were then placed at 5% CO2 37 ºC incubator until
confluence. The cells were dispersed by 0.25% (w/v) trypsin-0.53Mm EDTA solution and
re-plated on 8 well slides at a concentration of 1 X 105 cells/ml in DMEM10 medium for
24 hours at 5% CO2 37 ºC incubator. After this incubation, the cells adhered to the
bottom of the slides.
Then the medium was removed and the enteric neuronal cell line was plated on these
slides at a concentration of 5 X 105 cells/ml in N2 medium for 2-3 days at 33ºC incubator.
The slides cocultured astrocyte cell line and enteric neuronal cell line were then treated
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with anandamide (0, 1nM, 0.1uM, 10uM) diluted in neurobasal-A medium for 7 days at
5% CO2 39 ºC incubator. The medium was replaced once on day 3. The slides were
immunostained with anti-PGP9.5 antibody on day 7 (rabbit, Millipore) as described
above. Duplicate wells were done for each treatment in each experiment.

Counting of neuronal cells and calculations
The PGP9.5 immunoreactive cells were identified as the neuronal cells. The number of
neuronal cells and the number of total cells were counted in a 0.1215mm2 grid and three
randomly selected fields per well were examined. The neuronal cell percent was
calculated using the number of neuronal cells divided by the number of total cells per grid.
The percentage changes were calculated through the control divided by the treated groups.
Neuronal survival is expressed as the mean of percentage change of PGP9.5-positive cells
in total cells ±SEM.
In coculture slides, the astrocytes and enteric neuronal cells are easily differentiated and
neuronal survival is expressed as the mean of percentage change of PGP9.5-positive cells
in total enteric neuronal cells ±SEM.

Protein concentration assay and western blot analysis
Protein extraction
After treatment with anandamide, the enteric neuronal cells grown in 6 well plates were
prepared for protein exaction. The plates were rinsed with cold PBS twice and then
incubated in 0.3ml/well lysis buffer solution containing 50mM Tris/Cl, pH 7.5, 150mM
NaCl, 0.1%SDS, 0.5% Sodium deoxycholate, 1% NP-40, 10mM Sodium pyrophosphate
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and protease inhibitor cocktail (BD Biosciences) containing 16 ug/ml benzamidine HCl,
10 ug/ml phenanthroline, 10ug/ml aprotinin, 10ug/ml leupeptin, 10ug/ml pepstatin A, and
1mM PMSF for 1-2 minutes. The cells were scrapped off and sonicated for 10 seconds to
disrupt the cells. The samples were centrifuged for 20 minutes at 4 ºC. The supernatant
was then transferred to new vials for Biorad protein assay and western blot and the pellet
was discarded.
Biorad protein assay
The BSA standards (2.0, 1.2, 1.0 0.8, 0.6, 0.4, 0.2 and 0 mg/ml) were used for generating
a standard curve. The protein concentration of samples was determined from the X-axis
of the standard curve.
Western blot
The protein extracts were resolved using 10% SDS/PAGE gel and then transferred onto a
nitrocellulose membrane for two hours at 4ºC in 100-125 volts. After blocking with 5%
milk for one hour, the membranes were incubated with primary antibodies for 24 hours at
4ºC. The membranes were then washed three times with Tris Buffered Saline Tween-20
(TBST) buffer and incubated with Odyssey fluorescent secondary antibodies for one
hour. After three times washes with TBST, the membranes were developed by Odyssey.
The band intensities were quantitated by Odyssey software. For detecting the CB2
expression in enteric neuronal cell line, the horseradish peroxidase-conjugated secondary
antibody (1:1000) was used and the protein bands were identified by Supersignal west
femto chemiluminescent kit (Thermo scientific).

43

Statistics
The results are expressed as means + SEM. of n experiments and analyzed for statistical
significance using Student’s t-test or ANOVA. The probability of P<0.05 was considered
statistically significant.

Results

Ganglion isolation and growth
The myenteric ganglia were successfully isolated from the guinea pig small intestine, and
visualized in phase contrast microscopy (Figure 6, left panel). Then each well of the
culture plates was seeded with 15 ganglia and grown in DMEM 10 medium for 3 days; at
this stage the ganglia were attached to the floor of culture slides, and glia and neurons
began expanding their processes and neurites. Then the ganglia were grown in DMEM0
medium for 4 days and immunostained with an antibody to the general neuronal marker
PGP9.5. The enteric neurons can be easily identified after this process as shown in Figure
6 (right panel).

Effect of anandamide on ganglionic survival
After 7 days in culture, the average number of ganglia per well was 6.05±0.67 in the
control group (Figure not shown). The results with anandamide treatment indicated that
anandamide had a biphasic effect on ganglionic survival, increasing survival at low
concentrations (1nM-0.1uM) and decreasing survival at high concentration (10uM).
Maximal survival (68% increase in number of ganglia surviving) occurred at 0.1uM and
the ED50 was 3nM (Figure 7).
To differentiate which cannabinoid receptor(s) mediated these effects, primary cultures
were treated with anandamide and CB1 cannabinoid receptor antagonist, AM251 (1uM).
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Figure 6. Images of freshly isolated ganglia (left) and ganglia grown 7 days in culture
(right).
Left panel illustrates freshly isolated ganglia from guinea pig intestine and right panel
shows a ganglia grown 3 days in DMEM10 and another 4 days in DMEM0 culture
medium and immunostained with neuronal marker anti-PGP9.5 antibody.
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Figure 7. Anandamide dose response curve for ganglia survival in absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (1nM-10uM) in DMEM0 medium for 4 days. The number of ganglia was
counted on day 7 after immunostained with neuronal marker anti-PGP9.5 antibody.
Anandamide had a biphasic effect on ganglionic survival, increasing survival at low
concentrations (1nM-0.1uM) and decreasing survival at high concentration (10uM).
Maximal survival (68% increase in number of ganglia surviving) occurred at 0.1uM and
the ED50 was 3nM. Ganglionic survival is expressed as percentage change from control.
Values are means±SEM of 9 animals. * = P<0.05.
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As shown in Figure 8, anandamide induced increase in survival was inhibited by AM251,
suggesting this effect was mediated by CB1 receptors. The CB1 antagonist alone had no
effect on the number of ganglia surviving compared with control, suggesting endogenous
cannabinoids may not play a role in ganglia survival through CB1 receptor. In addition,
AM251 did not block the decreased survival of ganlia induced by the higher
concentration of anandamide (10uM) . This suggested that the decrease in survial of
ganglia was not due to CB1 receptors.
Next we examined whether CB2 receptors play a role in the ganglia survival. We used
the CB2 receptor specific antagonist AM630 to address this question. Again, anandamide
had a biphasic effect on ganglionic survival, increasing survival at low concentration
(0.1uM) and decreasing survival at high concentration (10uM). The effect of anandamide
on promoting survival was not inhibited by CB2 antagonist AM630 (1uM); however, the
effect on decreasing survival was significantly inhibited by AM630 (Figure 9). These
results suggested that high concentration of anandamide activate CB2 receptors and
decrease ganglia survival. The results also suggest that CB2 receptor was not involved in
the increase in ganglia survial induced by low concentrations of anandamide (0.1uM).
The CB2 antagonist alone had no effect on the cultured ganglia survival, suggesting
endogenous cannabinoid may not play a role in ganglia survival through CB2 receptor
(Figure 9).
The TRPV1 receptor can be found in extrinsic primary sensory neurons as well as
intrinsic sensory neurons. There are some evidence that anandamide could activate the
TRPV1 receptor, although at high concentrations. Here we tested whether the effect of
anandamide on ganglionic survival involved TRPV1. We found that both the
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Figure 8. Anandamide dose response curve for ganglia survival with CB1 antagonist in
absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated
additionally with the CB1 receptor antagonist, AM251 (1uM) on day 3. The number of
ganglia was counted on day 7 after immunostained with neuronal marker anti-PGP9.5
antibody. Anandamide had a biphasic effect on ganglionic survival, increasing survival at
low concentration (0.1uM) and decreasing survival at high concentration (10uM). The
effect of anandamide on increasing ganglia survival was inhibited by AM251. Ganglionic
survival is expressed as percentage change from control. Values are means±SEM of 9
animals. * = P<0.05.
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Figure 9. Anandamide dose response curve for ganglia survival with CB2 antagonist
AM630 in absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated
additionally with the CB2 receptor antagonist, AM630 (1uM) on day 3. The number of
ganglia was counted on day 7 after immunostained with neuronal marker anti-PGP9.5
antibody. Anandamide had a biphasic effect on ganglionic survival, increasing survival at
low concentration (0.1uM) and decreasing survival at high concentration (10uM). The
effect of anandamide on decreasing survival was significantly inhibited by AM630
(1uM). Ganglionic survival is expressed as percentage change from control. Values are
means±SEM of 15 animals for control and 6 animals for AM630. * = P<0.05.
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promoting and decreasing effects of anadamide on ganglia survival were not inhibited by
TRPV1 antagonist capsazepine (1uM). The TRPV1 antagonist alone also had no effect on
the cultured ganglia survival. These data suggest that the TRPV1 receptor may not play a
role in anandamide-mediated ganglia survival (Figure 10).Taken together, these data
suggest that anandamide promotes ganglia survival at low concentration (0.1uM) by
interaction with CB1 receptors and decreases ganglia survival at high concentration by
interaction with CB2 receptors.

Enteric glia involved in anandamide mediated ganglionic survival
The enteric ganglia included enteric neurons and enteric glia. Next, we examined the
effect of anandamide on the ganglion survival in absence of enteric glia cells. We used
cytosine arabinoside (araC) to inhibit rapidly dividing cells and to reduce most of the
enteric glia cells. After 7 days in culture with araC treatment, the average number of
ganglia was 4.83±1.97 in the control group (Figure not shown). The results with
anandamide treatment under these conditions are shown in Figure 11. Anandamide, at
low concentrations (1nM-0.1uM), had no effect on ganglionic survival in presence of
araC. So in the absence of enteric glia cells, anandamide lost its ability to promote
ganglia survival, suggesting this effect involved the glia cells. At higher concentration
10uM, anandamide inhibited the ganglia survival by 63% just as it did in the absence of
araC. AM251 did not reverse this inhibition, suggesting that the inhibition by anandamide
was not mediated by CB1 receptor. AM251 alone had no effect on the cultured ganglia
survival (Figure 12).
Next we want to know whether CB2 receptor still play a role in ganglia death in the
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Figure 10. Anandamide dose response curve for ganglia survival with TRPV1 antagonist
capsazepine in absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated
additionally with the TRPV1 receptor antagonist, capsazepine (1uM) on day 3. The
number of ganglia was counted on day 7 after immunostained with neuronal marker antiPGP9.5 antibody. Both promoting and decreasing survival were not inhibited by TRPV1
antagonist capsazepine. The TRPV antagonist alone also had no effect on the cultured
ganglia survival. Ganglionic survival is expressed as percentage change from control.
Values are means±SEM of 15 animals for control and 3 animals for capsazepine group. *
= P<0.05.
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Figure 11. Anandamide dose response curve for ganglia survival in presence of araC
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC;
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium
with araC for 4 days. The number of ganglia was counted on day 7 after immunostained
with neuronal marker anti-PGP9.5 antibody. Anandamide, at low concentrations (1nM0.1uM), had no effect on ganglionic survival in presence of araC. At high concentration
(10uM), anandamide inhibited the ganglia survival by 63%. Ganglionic survival is
expressed as percentage change from control. Values are means±SEM of 7 animals. * =
P<0.05.
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Figure 12. Anandamide dose response curve for ganglia survival with CB1 antagonist in
presence of araC
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC;
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium
with araC for 4 days. Some cultures were treated additionally with the CB1 receptor
antagonist, AM251 (1uM) on day 3. The number of ganglia was counted on day 7 after
immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide (10uM)
inhibited the ganglia survival by 63%, which was not reversed by AM251. Ganglionic
survival is expressed as percentage change from control. Values are means±SEM of 7
animals. * = P<0.05.
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absence of glia cells. As shown in Figure 13, again after reducing glia cells, anandamide,
at low concentrations (1nM-0.1uM), had no effect on ganglionic survival and inhibited
the ganglia survival at higher concentration (10uM). AM630 (1uM) reduced the level of
inhibition of growth by high concentrations of andamide (10 uM) but this did not achieve
significance, suggesting that CB2 receptors in both neurons and glia cells could
participate in high concentration anandamide induced ganglia death. The CB2 antagonist
alone had no effect on the cultured ganglia survival.
Taken together, these data suggested that enteric glia cells were involved in anandamide
mediated ganglion survival. Anandamide may act on CB1 receptors in enteric glia to
promote ganglia survival and on CB2 receptors in both enteric neurons and glia to inhibit
survival.

Effect of anandamide on neuronal survival
Next we want to know whether anandamide affected the enteric neuronal survival. We
examined the number of neurons in each ganglia and the total number of neurons in each
well. After 7 days in cultures, the number of neurons in each ganglion is 19.11±1.44
(Figure 14) and the number of total neurons in each well is 116.71±14.76 (Figure 15) in
control group. Anandamide (1nM-10uM) did not change the number of neurons/ganglion
significantly in presence of enteric glia (Figure 16), however, similar to the effect on
ganglia survival, anandamide tended to increase the survival of total neurons per well at
low concentrations (1nM-0.1uM) and decrease it at higher concentrations (1uM-10uM) in
the presence of enteric glia. Maximal survival (66% increase in number of total neurons)
occurred at 0.1uM (Figure 17). This data suggest anandamide could increase neuronal
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Figure 13. Anandamide dose response curve for ganglia survival with CB2 antagonist
AM630 in presence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC;
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium
with araC for 4 days. Some cultures were treated additionally with the CB2 receptor
antagonist, AM630 (1uM) on day 3. The number of ganglia was counted on day 7 after
immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide inhibited the
ganglia survival at higher concentration (10uM) and AM630 was not able to block this
inhibition significantly in the presence of araC. Ganglionic survival is expressed as
percentage change from control. Values are means±SEM of 4 animals. * = P<0.05.
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Figure 14. Effect of CB1 antagonist on neurons in ganglia in absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
the CB1 receptor antagonist, AM251 (1uM) in DMEM0 medium for 4 days. The number
of neurons in ganglia was counted on day 7 after immunostained with neuronal marker
anti-PGP9.5 antibody. CB1 antagonist AM251 (1uM) alone had no effect on the number
of neurons/ganglion in the absence of araC. Neuronal survival is expressed as the number
of neurons per ganglia. Values are means±SEM of 9 animals.
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Figure 15. Effect of CB1 antagonist on total neurons per well in absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
the CB1 receptor antagonist, AM251 (1uM) in DMEM0 medium for 4 days. The number
of total neurons per well was counted on day 7 after immunostained with neuronal
marker anti-PGP9.5 antibody. CB1 antagonist AM251 (1uM) alone had no effect on the
number of total neurons per well in the absence of araC. Neuronal survival is expressed
as the number of neurons per ganglia. Values are means±SEM of 9 animals.
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Figure 16. Neurons in ganglia dose response to anandamide in absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (1nM-10uM) in DMEM0 medium for 4 days. The number of neurons in
ganglia was counted on day 7 after immunostained with neuronal marker anti-PGP9.5
antibody. In the absence of araC, anandamide (1nM-10uM) did not change the number of
neurons/ganglion significantly. Neuronal survival is expressed as percentage change from
control. Values are means±SEM of 9 animals.
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Figure 17. The number of total neurons per well dose response to anandamide in absence
of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (1nM-10uM) in DMEM0 medium for 4 days. The number of total neurons
per well was counted on day 7 after immunostained with neuronal marker anti-PGP9.5
antibody. Anandamide tended to increase the survival of total neurons per well at low
concentrations (1nM-0.1uM) and decrease it at higher concentrations (1uM-10uM) in the
absence of araC. Maximal survival (66% increase in number of total neurons) occurred at
0.1uM. Neuronal survival is expressed as percentage change from control. Values are
means±SEM of 9 animals.
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survival through promoting the ganglionic survival, which is mediated by CB1 receptors.
AM251 (1uM) alone had no effect on the number of neurons/ganglion (Figure 14) and
the number of total neurons/well (Figure 15), suggesting endogenous cannabinoids may
not be involved in neuronal survival through the CB1 receptor. Treatment with
anandamide and AM251 together did not change the number of neurons/ganglion either
(Figure 18). However, AM251 (1uM) tended to inhibit the effect of anandamide on total
neuronal survival (Figure 19). This effect may also have been the result of the effect of
AM251 on ganglion survival.
Treatment with anandamide (0.1uM) and AM630 together, significantly increased the
neuronal survival in ganglia by 35%. AM630 alone also tended to increase neuronal
survival in ganglia (Figure 20). In addition, AM630 increased total neuronal survival per
well significantly when added alone or in combination with anandamide (10uM) (Figure
21). These data suggested that blockade of CB2 receptor may increase neuronal survival
in the presence of glia and suggests that activation of CB2 receptors inhibits neuronal
suvival in the presence of glia.

Inhibition of neuronal survival by anandamide in absence of enteric glia
As described earlier, we reduced the enteric glia cells by araC to distinguish the direct
role of anandamide on neuronal survival. Low concentrations of anandamide (1nM0.1uM) decreased the number of neurons/ganglion by 15-20% in the presence of araC
(Figure 22). At higher concentrations, anandamide also (1nM-10uM) decreased the
number of total neurons per well by 13-66% in the presence of araC (Figure 23). These
data suggested that anandamide inhibited neuronal survival when enteric glia cells were
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Figure 18. Neurons in ganglia dose response to anandamide with CB1 antagonist in
absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated
additionally with the CB1 receptor antagonist, AM251 (1uM) on day 3. The number of
neurons in ganglia was counted on day 7 after immunostained with neuronal marker antiPGP9.5 antibody. In the absence of araC, anandamide (1nM-10uM) alone or treated with
AM251 together did not change the number of neurons/ganglion significantly. Neuronal
survival is expressed as percentage change from control. Values are means±SEM of 9
animals.
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Figure 19. The Number of total neurons per well dose response to anandamide with CB1
antagonist in absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated
additionally with the CB1 receptor antagonist, AM251 (1uM) on day 3. The number of
total neurons per well was counted on day 7 after immunostained with neuronal marker
anti-PGP9.5 antibody. Anandamide tended to increase the survival of total neurons per
well at low concentrations (1nM-0.1uM) and decrease it at higher concentrations (1uM10uM) in the absence of araC. Maximal survival (66% increase in number of total
neurons) occurred at 0.1uM. AM251 (1uM) tended to inhibit the effect of anandamide at
low concentrations. Neuronal survival is expressed as percentage change from control.
Values are means±SEM of 9 animals.

% Change from control

76

125
100

AEA
+AM251

75
50
25
0
-25
-50
-75
-100

0

-9

-8

-7

-6

Anandamide (logM)

-5

77

Figure 20. Neurons in ganglia dose response to anandamide with CB2 antagonist AM630
in absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated
additionally with the CB2 receptor antagonist, AM630 (1uM) on day 3. The number of
neurons in ganglia was counted on day 7 after immnostained with neuronal marker antiPGP9.5 antibody. Treatmentment anandamide (0.1uM) and AM630 together, AM630
significantly promote the neuronal survival in ganglia by 35%. Neuronal survival is
expressed as percentage change from control. Values are means±SEM of 15 animals for
control and 6 animals for AM630. * = P<0.05.
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Figure 21. The Number of total neurons per well dose response to anandamide with CB2
antagonist AM630 in absence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (1nM-10uM) in DMEM0 medium for 4 days. Some cultures were treated
additionally with the CB2 receptor antagonist, AM630 (1uM) on day 3. The number of
total neurons per well was counted on day 7 after immmnuostained with neuronal marker
anti-PGP9.5 antibody. AM630 promoted the total neuronal survival per well significantly
when treated with anandamide (10uM) together. Neuronal survival is expressed as
percentage change from control. Values are means±SEM of 15 animals for control and 6
animals for AM630 group. * = P<0.05.
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Figure 22. Neurons in ganglia dose response to anandamide in presence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC;
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium
with araC for 4 days. Some cultures were treated additionally with the CB1 receptor
antagonist AM251 (1uM) on day 3.The number of neurons in ganglia was counted on day
7 after immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide (1nM0.1uM) decreased the number of neurons/ganglion by 15-20% in the presence of araC.
Data was shown in doses 10nM and 10uM. Neuronal survival is expressed as percentage
change from control. Values are means±SEM of 7 animals. * = P<0.05.
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Figure 23. The Number of total neurons per well dose response to anandamide in
presence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC;
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium
with araC for 4 days. Some cultures were treated additionally with the CB1 receptor
antagonist, AM251 (1uM) on day 3. The number of total neurons per well was counted
on day 7 after immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide
(1nM-10uM) decreased the number of total neurons per well by 13-66% in the presence
of araC. Data was shown in doses 10nM and 10uM. Neuronal survival is expressed as
percentage change from control. Values are means±SEM of 7 animals. * = P<0.05.

84

% Change from control

0

AEA

-25
-50
-75

*

-100
0

-8

Anandamide log(M)

-5

85

not present in the cultures. This is very different from the condition in the presence of glia
(i.,e., absence of araC,) where anadamide had a biphasic effect on the number of total
neurons, increasing the number of neurons at low concentrations and decreasing the total
number of neurons at higher concentrations (see Figure 17).
The decrease in the number of neurons/ganglion was partially reversed by AM251 (1uM)
(Figure 24 and 25), which suggested that inhibition of anandamide on the neuronal
survival was partially mediated by CB1 receptors. In addition, AM251 (1uM) tended to
inhibit the effect of anandamide on the number of total neurons/well at low
concentrations (1nM-0.1uM) although not significantly, and had no significant effect at
the highest concentration of anandamide (10uM). Again, AM251 alone had no effect on
the neuronal survival in the presence of araC (Figure 25).
Next, we wanted to know whether this inhibition by anandamide also involved CB2
receptors. The results showed that again, anandamide (1nM-0.1uM) decreased the
number of neurons/ganglion by 17-30% in the presence of araC and this was not
significantly blocked by AM630 (1uM) although there was a tendency to reduce the
effect of anadamide by AM630. AM630 alone had no significant effect on the number of
neurons/ganglion in the presence of araC (Figure 26). AM630 (1uM) was also not able to
significantly inhibit the effect of anandamide on the number of total neurons per well in
the presence of araC (Figure 27). Although the effects of AM630 did not achieve
statistical significance, they did revese the effects of anandamide at all but the highest
concentration. These data suggested that CB2 receptors are likely to be involved in
anandamide mediated neuronal death in absence of enteric glia.
Taken together, anandamide decreased neuronal survival without enteric glia cells, which
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Figure 24. Neurons in ganglia dose response to anandamide with CB1 antagonist in
presence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC;
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium
with araC for 4 days. Some cultures were treated additionally with the CB1 receptor
antagonist AM251 (1uM) on day 3.The number of neurons in ganglia was counted on day
7 after immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide (1nM0.1uM) decreased the number of neurons/ganglion by 15-20% in the presence of araC.
This effect was partially reversed by CB1 antagonist, AM251 (1uM). Data was shown in
doses 10nM and 10uM. Neuronal survival is expressed as percentage change from
control. Values are means±SEM of 7 animals. * = P<0.05.
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Figure 25. The Number of total neurons per well dose response to anandamide with CB1
antagonist in presence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC;
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium
with araC for 4 days. Some cultures were treated additionally with the CB1 receptor
antagonist, AM251 (1uM) on day 3. The number of total neurons per well was counted
on day 7 after immunostained with neuronal marker anti-PGP9.5 antibody. Anandamide
(1nM-10uM) decreased the number of total neurons per well by 13-66% in the presence
of araC, which was partially blocked by AM251. AM251 did not significantly change the
effect of anandamide at 10uM. Data was shown in doses 10nM and 10uM. Neuronal
survival is expressed as percentage change from control. Values are means±SEM of 7
animals. * = P<0.05.
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Figure 26. Neurons in ganglia dose response to anandamide with CB2 antagonist AM630
in presence of araC.
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC;
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium
with araC for 4 days. Some cultures were treated additionally with the CB2 receptor
antagonist, AM630 (1uM) on day 3. The number of neurons in ganglia was counted on
day 7 after immnuostained with neuronal marker anti-PGP9.5 antibody. Anandamide
(1nM-0.1uM) decreased the number of neurons/ganglion by 17-30% in the presence of
araC. This was partially blocked by AM630 (1uM). Data was shown in doses 10nM and
10uM. Neuronal survival is expressed as percentage change from control. Values are
means±SEM of 4 animals. * = P<0.05.
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Figure 27. The Number of total neurons per well dose response to anandamide with CB2
antagonist AM630 in presence of araC
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium with cytosine arabinoside (araC;
10uM) for 3 days and then treated with anandamide (1nM-10uM) in DMEM0 medium
with araC for 4 days. Some cultures were treated additionally with the CB2 receptor
antagonist, AM630 (1uM) on day 3. The number of total neurons per well was counted
on day 7 after immunostained with neuronal marker anti-PGP9.5 antibody. AM630
(1uM) partially inhibit the effect of anandamide on neuronal death in the presence of
araC. Data was shown in doses 10nM and 10uM. Neuronal survival is expressed as
percentage change from control. Values are means±SEM of 4 animals. * = P<0.05.

93

% Change from control

50

AEA
+AM630

0

-50

-100
0

-8

Anandamide log(M)

*-5

94

could be mediated by CB1 and CB2 receptors. The inhibition by lowest levels of
anadamide is most sensitive to the CB antagonists whereas the inhibition induced by the
highest level of anandamide is less sensitive. This data also demonstrates that the effect
of anandamide is highly dependent on whether glial are present or absent from the
cultures and suggests that glial may respond to cannabinoids and alter the overall effect
of anandamide. We examined this in later studies of this thesis project.

Inhibition of enteric neuronal cell survival by anandamide
To confirm the direct inhibitory effect of anandamide on neuronal survival, we examined
the newly developed immorto fetal enteric neuronal cell line (IM-FEN). Phase contrast
images confirmed that the enteric cell line proliferated at 33 degree and differentiated to
form neurites at 39 degree (Figure 28). Consistent with the production of neurites, most
of the cells expressed the neuronal marker PGP9.5 (Figure 29); this is consistant with the
report by Dr. S. Srinivasan’s group at Emory University who supplied the cell line to us.
In addition, this cell line was able to form ganglion-like structures and these structures
further connected to the complicate networks.
Anandamide treatment at 39 degree had no effect on the number of total cells (Data not
shown), however, it decreased neuronal cell percentage in a concentration-dependent
manner (11-45% decrease in survival at 1nM-10uM) (Figure 30). While this is consistent
with the effect of anandamide to inhibit neuronal survival in primary cultures as
described above, the effect in the cell line could be due to the neuronal cell death or
differentiation to non-neuronal cells or both.
To partly address this question, we treated the cells with anandamide at 33 degree to
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Figure 28. Phase contrast images of enteric cell line cultured at 33 and 39 degree.
Cells was proliferated at 33 degree, and after cultured at 39 degree for 7 days they began
to differentiate with neurites.
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Figure 29. Neuronal marker PGP9.5 expression in enteric neuronal cell line (IM-FEN).
The cells were cultured in 33 degree for 2-3 days and then grown at 39 degree for 7 days.
Immunofluoresence staining was performed with anti-PGP9.5 antibody and image was
shown in right panel. Most of cells expressed neuronal marker PGP9.5. Negative control
was shown in left panel.
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Figure 30. Anandamide dose response curve for enteric neuronal cell line at 39 degree.
Enteric neuronal cell line (IM-FEN) was cultured in 33 degree for 2-3 days and then
move to 39 degree treated with anandamide (1nM-10uM) in neural basal A medium for 7
days. The medium was changed once on day 3. The effect of anandamide on neuronal
survival was measured by counting cells immunostained with anti-PGP9.5 antibody.
Anandamide treatment at 39 degree decreased neuronal cells percentage in a
concentration-dependent manner (11-45% decrease in survival at 1nM-10uM). The
number of total cells had no significant change among groups (Data not shown).
Neuronal survival is expressed as percentage change of PGP9.5-positive cells in total
cells. Values are mean ±SEM of 4 experiments. * = P<0.05.
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eliminate the effect of anandamide on cell differentiation at 39 degree. Anandamide also
decreased neuronal survival in a concentration-dependent manner at 33 degree (10-22%
decrease in survival at 1nM-10uM) (Figure 31). This further support the idea that
anandamide could inhibit neuronal survival in this enteric neuronal cell line.

Effect of anandamide on cocultures of enteric cell line and astrocytes
Next we want to know whether co-culture enteric cell line with glia could reverse
anandamide-decreased neuronal survival. This question was based on the findings in
primary cultures where the presence of glia altered the effect of anandamide. Getting
enough of primary enteric glia takes a very long time (months are required to obtain a
few coverslips) because these cells divide very slowly. To address this question in some
manner, we used a commercially available astrocyte cell line, which was isolated from
mice brain. Astrocytes were chosed becasue the enteric glial cells are most closely related
to astrocytes. At the time of these studies, enteric glial cells were not available
commercially. Unfortunately, this cell line was not able to inhibit anandamide-induced
neuronal cell death (Figure 32). This lack of effect is likely due to the fact that the cells
were not truly enteric glial cells and there neither supports or rejects our hypothesis
relative to the role of glial cells in the response to andamide.

Taken together with previous data, it illustrated that anandamide may act on CB1
receptors in enteric glia to promote ganglia survival and on CB2 receptors in enteric glia
to inhibit survival. Anandamide also inhibited neuronal survival in absence of enteric glia
which could be mediated by CB1 and CB2 receptors and inhibited the enteric neuronal
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Figure 31. Anandamide dose response curve for enteric neuronal cell line at 33 degree.
Enteric neuronal cell line (IM-FEN) was cultured in 33 degree treated with anandamide
(1nM-10uM) in DMEM/F12 medium for 2-3 days and then moved to 39 degree without
anandamide teatment for 7 days. The medium was changed once on day 3. The effect of
anandamide on neuronal survival was measured by counting cells immunostained with
PGP9.5. Anandamide decreased neuronal survival in a concentration-dependent manner
at 33 degree. (10-22% decrease in survival at 1nM-10uM). Neuronal survival is
expressed as percentage change of PGP9.5-positive cells in total cells. Values are mean
±SEM of 3 experiments. * = P<0.05.
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Figure 32. Anandamide dose response curve for enteric neuronal cell line cocultured with
astrocyte cell line at 39 degree.
Enteric neuronal cell line (IM-FEN) was co-cultured with astrocyte cell line at 33 degree
in DMEM/F12 medium for 2-3 days and then moved to 39 degree treated with
anandamide (1nM-10uM) in neural basal A medium for 7 days. The medium was
changed once on day 3. The effect of anandamide on neuronal survival was measured by
counting cells immunostained with anti-PGP9.5 antibody. The astrocyte cell line was not
able to inhibit anandamide-induced neuronal cell death. Neuronal survival is expressed as
percentage change of PGP9.5-positive cells in total cells. Values are mean ±SEM of 3
experiments. * = P<0.05.
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cell line in both 33 and 39 degrees.

CB1 and CB2 expression in primary cultures and enteric neuronal cell line
Immunofluoresence staining showed that CB1 receptors are not only expressed in enteric
neurons but also in enteric glia cells in primary cultures. However, enteric glia CB1
expression is lower than in enteric neurons. Interestingly, enteric glia cells with
concentrated cell bodies had strong S100 and CB1 staining and when cell bodies spread
out, the staining density became lower (Figure 33).
CB2 receptors are also expressed in both enteric neurons and glia cells in primary
cultures. There are similar staining densities between neurons and glia. CB2 expression
was evenly distributed in the glia cell body (Figure 34).
Both CB1 and CB2 receptors were expressed in enteric neuronal cell line, which were
supported by immunofluoresence staining (Figure 35) and western blot results (Figure
36). The protein extractions from spleen tissue of guinea pig and mice were used as a
positive control in western blot for CB2 antibody. (Data not shown)

Anandamide activated downstream signaling pathways in ganglia
Next, we want to know which downstream signaling pathway(s) was involved in
anandamide mediated ganglia survival in the presence of glial (i.e.,absence of araC). We
tested the MAPK pathway, PLC-beta pathway and PI3K/AKT pathway by using their
inhibitors. The results are shown in Figure 37. Again, 0.1uM anandamide increased the
ganglia survival in absence of araC. The PLC-beta inhibitor U73122 (1uM) alone had no
significant effect on the ganglia survival (Data not shown), however, it inhibited
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Figure 33. CB1 expression in primary cultures of enteric ganglia
Primary cultures of enteric ganglia were prepared from guinea pig intestine and grown in
DMEM10 medium for 7 days. CB1 receptor expression was determined by
immunofluoresence co-staining anti-CB1 antibody with neuronal marker PGP9.5 or glia
marker S100. CB1 receptors are not only expressed in enteric neurons but also in enteric
glia cells in primary cultures. Middle left: PGP9.5 (green), middle right: CB1 (red),
bottom left: S100 (green), bottom right: CB1 (red). Negative controls are shown in top
two. Arrows indicate examples of positive staining for enteric neurons. Arrowheads
indicate examples of positive staining for enteric glia.
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Figure 34. CB2 expression in primary cultures of enteric ganglia
Primary cultures of enteric ganglia were prepared from guinea pig intestine and grown in
DMEM10 medium for 7 days. CB2 receptor expression was determined by
immunofluoresence co-staining anti-CB2 antibody with neuronal marker PGP9.5 or glia
marker S100. CB2 receptors are expressed both in enteric neurons and glia cells in
primary cultures. Top left: PGP9.5 (green), top right: CB2 (red), bottom left: S100
(green), bottom right: CB2 (red). Arrows indicate examples of positive staining for
enteric neurons. Arrowheads indicate examples of positive staining for enteric glia.
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Figure 35. CB1 and CB2 receptors expression in enteric neuronal cell line (IM-FEN) by
immunocytochemistry.
The cells were cultured in 33 degree for 2-3 days and then grown at 39 degree for 7 days.
Immunofluoresence staining was performed with anti-CB1 or anti-CB2 antibodies and
images were shown in left and right side respectively. Both CB1 and CB2 receptors were
expressed in enteric neuronal cell line.
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Figure 36. CB1 and CB2 receptors expression in enteric neuronal cell line (IM-FEN)
The cells were cultured in 33 degree for 2-3 days and then grown at 39 degree for 7 days.
Protein extracts were immunobloted with either anti-CB1 or anti-CB2 antibodies and
CB1 (60 KDa) and CB2 (38 KDa) bands are shown. Both CB1 and CB2 receptors were
expressed in enteric neuronal cell line. Protein markers were shown in left side.
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Figure 37. Anandamide mediated downstream signaling pathway
Primary cultures of enteric ganglia were prepared from guinea pig intestine. Each well
was seeded with 15 ganglia grown in DMEM10 medium for 3 days and then treated with
anandamide (0.1uM) in DMEM0 medium for 4 days. Some cultures were treated
additionally with the MAPK inhibitor PD98059 (1uM), PLC inhibitor U73122 (1uM),
and PI3K inhibitor LY-294002 (1uM) on day 3. The number of ganglia was counted on
day 7 after immunostained with neuronal marker anti-PGP9.5 antibody. Again, 0.1uM
anandamide increased the ganglia survival in absence of araC. PLC inhibitor U73122
(1uM) alone had no significant effect on the ganglia survival (data not shown); however,
it inhibited anandamide induced ganglia survival significantly. PD98059 and LY-294002
also inhibited anandamide induced ganglia survival, although not significantly.
Ganglionic survival is expressed as percentage change from control. Values are
means±SEM of 6 animals. * = P<0.05.
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anandamide induced ganglia survival significantly, suggesting the effect of anandamide
on promoting ganglia survival is mainly mediated by PLC pathway. A role of MAPK and
PI3K/AKT is less well supported since antagonists of these pathways caused slight but
nonsignificant inhibition of the effects of anandamide. We were not able to measure the
anandamide downstream pathways by western blot in that this is a complex of enteric
neurons and glia.

Anandamide activated downstream signaling pathways in the enteric neural cell
line.
In the enteric neural cell line (IM-FEN), we tested the downstream signaling pathways
involved in anandamide mediated enteric neuronal death by western blot and use of the
selective antagonists. Firstly, we treated the enteric cell line with MAPK, PLC-beta, and
PI3K inhibitors and examined the total cell survival. The PLC-beta inhibitor U73122
(10uM) decreased the total cells by nearly 40% (Figure 38), which made us unable to
examine the effect of this compound on the neuronal percentage further. Next, we wanted
to know whether the MAPK and PI3K inhibitors affect the anandamide mediated
neuronal cell death. We used 10uM anandamide to inhibit the neuronal survival becasue
the inhibition at this concentration was most significant. As shown in Figure 39,
treatment with anandamide (10uM) and PD98059 (10uM) together increased
anandamide-mediated inhibition up to 136%, suggesting that the MAPK pathway may
protect the neuronal cells from anandamide induced death. In contrast, combination of
anandamide (10uM) and LY-294002 (10uM) decreased anandamide-mediated inhibition
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down to 35%, suggesting PI3K could mediate the inhibition of anandamide on neuronal
percentage.

Figure 38. Effect of MAPK, PLC and PI3K inhibitors on the number of total cells at 39
degree
Enteric neuronal cell line (IM-FEN) was cultured in 33 degree for 2-3 days and then
moved to 39 degree treated with MAPK inhibitor PD98059 (10uM), PLC inhibitor
U73122 (10uM), or PI3K inhibitor LY-294002 (10uM) in neural basal A medium for 7
days. The medium was changed once on day 3. The effect of MAPK, PLC and PI3K
inhibitors on the number of total enteric cell line was counted. U73122 (10uM) treatment
at 39 degree decreased the number of total cells nearly 40%. Values are mean ±SEM of 3
experiments. * = P<0.05.
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Figure 39. Effect of MAPK and PI3K inhibitors on the percentage of neuronal cells at 39
degree
Enteric neuronal cell line (IM-FEN) was cultured in 33 degree for 2-3 days and then
move to 39 degree treated with 10uM anandamide and MAPK inhibitor PD98059 (10uM)
or PI3K inhibitor LY-294002 (10uM) in neural basal A medium for 7 days. The medium
was changed once on day 3. The effect on neuronal survival was measured by counting
cells immunostained with anti-PGP9.5 antibody. The inhibition of 10uM anandamide in
neuronal survival was normalized as 100. Treatment with anandamide (10uM) and
PD98059 (10uM) together increased anandamide-mediated inhibition up to 136%,
suggesting MAPK may protect the neuronal cells from anandamide induced death.
Treatment with anandamide (10uM) and LY-294002 (10uM) together decreased the
inhibition down to 35%, suggesting PI3K could mediate the inhibition of anandamide on
neuronal percentage. Neuronal survival is expressed as percentage change of PGP9.5positive cells in total cells. Values are mean ±SEM of 3 experiments.
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We further tested whether anandamide treatment altered the expression of p-MAPK and
p-AKT by western blot. The representative bands of p-MAPK were shown in Figure 40.
The quantitative results showed the expression of phospho-P44/42MAPK level was
increased by 13-48% after treatment with anandmide. MAPK activation was increased
most (48% increase) with 1nM anandamide treatment, and then this increase became less
(36% and 13% increase, respectively) with anandamide up to 0.1uM and 10uM (Figure
41). The representative bands of p-AKT were shown in Figure 42. The quantitative
results showed the expression of p-AKT level was dose-dependently increased with
anandamide treatment (1nM-10uM) (Figure 43). These data support the idea mentioned
earlier (see Figure 34) that MAPK and PI3K/AKT pathways were involved in
anandamide-mediated inhibition of neuronal survival. We further compared the
anandamide-induced change in p-MAPK and p-AKT with the anandamide induced
inhibition in neuronal percentage. The curve of MAPK activation had a similar trend with
the neuronal percentage inhibition and AKT activation was continually increased even
when the neuronal percentage was decreased (Figure 44). The two curves crossed at
around 1uM anandamide. These data suggested that the ratio of p-MAPK and p-AKT (i.e.
the increasing p-AKT and the decreasing p-MAPK with increasing anandamide
concentration) could be the cause of the anandamide-mediated inhibition in neuronal
survival.
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Figure 40. Representative western blots of P-P42/44MAPK from enteric neuronal cell
line treated with anandamide.
Enteric neuronal cell line (IM-FEN) was cultured in 33 degree for 2-3 days and then
moved to 39 degree treated with anandamide (1nM-10uM) in neural basal A medium for
7 days. The medium was changed once on day 3. The cell lysate was immunobloted for
P-P42/44MAPK. The membrane was striped and rebloted for P42/44 MAPK as control.
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Figure 41. Quantitative analysis of phosphorylation of P42/44MAPK.
The band intensities were quantitated by odyssey software and the ratio of PP42/44MAPK to P42/44MAPK was calculated as expression of phospho-P42/44MAPK.
The expression of phospho-P44/42MAPK level was increased by 13-48% after treatment
with anandmide (1nM-10uM). MAPK activation was increased by 48% with 1nM
anandamide treament, and then this increase was less (36% and 13%, respectively) with
increasing anandamide concentration to 0.1uM and 10uM. Values are relative changes
compared with control and expressed as mean±SEM of 5 experiments. * = P<0.05.
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Figure 42. Representative western blots of P-AKT from enteric neuronal cell line treated
with anandamide.
Enteric neuronal cell line (IM-FEN) was cultured in 33 degree for 2-3 days and then
moved to 39 degree treated with anandamide (1nM-10uM) in neural basal A medium for
7 days. The medium was changed once on day 3. Protein extract was immunobloted for
P-AKT. The membrane was stripped and reblotted for total AKT as control.
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Figure 43. Quantitative analysis of P-AKT
The band intensities were quantitated by odyssey software and the ratio of P-AKT to
AKT was calculated as expression of P-AKT. P-AKT level was dose-dependently
increased with anandamide (1nM-10uM) treatment. Values are relative changes
compared with control and expressed as mean±SEM of 3 experiments.
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Figure 44. Comparison of MAPK and AKT signalings with the inhibition of neuronal
survival by anandamide
The curve of MAPK activation had a similar trend with the neuronal percentage after
anandamide treatment. AKT activation was continually increased even when the neuronal
percentage was decreased. The two curves crossed at around 1uM anandamide. These
data suggested that the ratio of p-MAPK and p-AKT could be related to anandamidemediated inhibition on neuronal survival.
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Discussion

Expression of CB1 in myenteric neurons and glia
The enteric ganglion is composed of both neurons and glia. The expression of CB1
receptors by enteric neurons has been well characterized (79-83,85,87,88). However,
their expression by enteric glia is not clear, although there is ample evidence that they
were present in astrocytes (140-144), microglial cells (91,145-152) and oligodendrocytes
of the central nervous system (149). Here we show that CB1 receptors are not only
expressed in enteric neurons but also in enteric glia in primary cultures of myenteric
ganglia from guinea pig, which can play a relevant role in anandamide mediated
ganglionic survival.
Anandamide promotes ganglionic and neuronal survival in presence of enteric glia
In the present study, the effect of anandamide and cannabinoid receptors on primary
cultures of myenteric ganglia and neuron survival was summarized in Table 4.
The effect of cannabinoids on neuronal survival has been studied by many groups,
however, the results are controversial varying from neuroprotection (128-132) to
neurotoxity (133-134). Cannabinoid neuroprotection is usually more evident in wholeanimal than in cultured-neuron models, which may result from their impact on various
brain cell types (neurons, glia, vascular endothelium (153). In the present study, we have
shown that anandamide increased neuronal survival through promoting the ganglionic
survival in presence of glia, and that this effect is mediated by CB1 receptor.
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Table 4. The effect of anandamide and cannabinoid receptors in primary cultures of
myenteric ganglia and neuron survival
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Ganglia survival
Anandamide
(AEA)

+ glia

CB1 activation

+ glia

CB2 activation

+ glia

TRPV1
Anandamide
(AEA)

+ glia
- glia

CB1

- glia

CB2

- glia

TRPV1

- glia

Biphasic;
Promoting ganglia
survival at 1nM0.1uM;
Inhibiting ganglia
survival at 10uM
Mediate AEAinduced promoting
ganglia survival
Mediate 10uM
AEA-induced
inhibiting ganglia
survival
No effect
Inhibition of
ganglia survival at
10uM
No effect

Partially mediate
10uM AEAinduced inhibiting
ganglia survival
Not tested

Neuron/ganglia
survival
No effect

Total neuron/well
survival
Promoting total
neuron survival at
1nM-0.1uM

No effect

Mediate AEA
induced promoting
neuron survival
Mediate 10uM
AEA induced
inhibition of
neuron survival
Not tested
Inhibition of total
neuron survival at
10uM
No effect

Inhibition of
neuron/ganglion
survival
Not tested
Inhibition of
neuron/ganglion
survival
Partially mediate
AEA induced
inhibition of
neuron survival
Partially mediate
AEA induced
inhibition of
neuron survival
Not tested

Partially mediate
10uM AEA
induced inhibition
of neuron survival
Not tested

136

This clearly suggested glia could play an indispensable role in cannabinoid-mediated
neuroprotection. However, the exact mechanism is still not clear. Some studies have
shown that cannabinoids protect glial cells from ceramide induced apoptosis in vivo and
in vitro (154) and from oxidative stress damage through CB1 receptors (155). In addition,
CB1 receptor-mediated neuroprotection might result from cross-talk to the growth factor
system. For example, chronic exposure to Δ9-THC up-regulated brain derived
neurotrophic factor (BDNF) in specific brain areas in vivo (156) and BDNF is known to
be involved in CB1 receptor-dependent protection against excitotoxicity (157). Thus,
anandamide could protect enteric glia from death thereby maintaining the ganglia
integrity and also transactivate the tyrosine kinase receptors to protect ganglionic and
neuronal survival.
Anandamide promotes ganglionic survival through CB1 and PLC-beta primarily
CB1 receptors are G protein-coupled seven-transmembrane receptors (GPCR) (158).
They are preferentially coupled to PTX-sensitive Gi/o proteins (33-34). Recently some
studies showed they could also couple to Gq/11 proteins (144,159-160). Activation of
CB1 receptors can activate PLC-beta in a PTX-sensitive manner mediated by the Gi/o βγ
subunits (161-163) or PTX-insensitive manner mediated by the Gq/11 (144,159-160). In
the present study, we show that anandamide mediated ganglionic survival was blocked by
the PLC-beta inhibitor U73122, suggesting this effect was mediated by the PLC-beta
pathway. However, whether it is Gi/o or Gq/11 mediated has not been tested yet.
Context-specific activation of G proteins could partially explain the complexity of
cannabinoid effect in the nervous system. In addition, it is not completely clear where
activation exactly happens: enteric neurons or glia. Some studies suggest that the
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cannabinoid agonist WIN 55212-2 could activate the CB1 receptor in astrocytes directly
to induce Ca2+ elevation through activation of PLC-beta (144). Our studies also suggest
that there may be a possibility that the effect of cannabinoids on ganglionic survival
activates the MAPK and PI-3K/AKT pathways but to a lesser extent than the PLC-beta
pathway. Using the selective antagonists of these pathways, we found a tendency to
decrease ganglionic survival although this decrease did not achieve statistical
significance.
CB2 expression in enteric neurons and glia
The CB2 receptor was originally found in immune cells, where one of its roles being to
modulate cytokine release (49). Later it was detected morphologically and functionally in
neurons in central nervous system (164) and enteric nervous system (89). In the present
study, we also show that CB2 receptors are expressed in enteric neurons in primary
cultures of myenteric ganglia from guinea pig. In addition, we found that enteric glia
expresses CB2 in this culture condition as well. This is in contrast with other studies,
which did not observe CB2 receptor expression on enteric glia under normal conditions
and in the LPS-treated tissues for 2 hours in whole mount preparations of the rat
myenteric plexus (89). This difference could be explained in several ways. It could be
that CB2 expression was inducible in enteric glia by culturing up to 7 days. In this point,
enteric glia could have certain microglial properties. Since studies have shown that
microglial cells in primary cultures are intrinsically activated or “primed” because of the
procedures involved in transferring these cells into culture (165) and primed microglia
prepared from human, rat or mouse tissue express CB2 receptors (91,146-148,166-168).
It could also be that our primary cultures have the advantage that glia cells spread out and
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attach to the bottom of wells instead of wrapping together with neurons and ganglia, as
they would in the whole mount preparations, thus providing increased access to
immunostaining and visualization of the CB2 staining. In addition, it could be a species
difference in that our stuidies were done in guinea pig whereas the other studies were
done in rat whole mounts.
Enteric glia were found in enteric ganglia, the interconnecting nerve strands of the
ganglionated plexuses (14). Subsequently, enteric glia bodies and processes were clearly
demonstrated within the mucosal plexus (15-17), and glial processes make close contacts
with the epithelial cell layer (15,17-20). Interestingly, CB2 immunoreactivity was
detected in the epithelium of colonic tissue from inflammatory bowel disease (88). This
suggests a role for this receptor in inflammation, although whether it is expressed by
enteric glia in mucosal plexus have not been tested.
Role of CB2 in myenteric ganglionic survival
Activation of CB2 receptors has been implicated to be actively involved in the gut
response to inflammation including decreasing motility (111) and inhibiting local
histological damage (112). In addition, activation of CB2 receptors reduced the basal
sensitivity and the TNBS colitis-induced hypersenstitivity to colorectal distension in rats
(115) and inhibited the endogenous immunogenic agent bradykinin response in murine
mesenteric afferent nerve activity (169).
There are few data about the role of CB2 receptors in astrocytes and most studies about
CB2 function in glia came from microglial cells involving an anti-inflammatory role. (For
review, see 168). Studies have shown that stimulation of CB2 receptors by 2-AG
increases Erk activity in monocytes and increases migration of monocytes (73,170-172).

139

CB2 receptor activation decreases the in vitro production of proinflammatory molecules
in rat microglial cells (147, 173), and human microglial and THP-1 cells (174). More
recently the studies show that activation of CB2 receptors by 10uM anandamide inhibits
LPS/IFNγ-induced production of IL-12 (p35/40) and IL-23 (p19/p40) through ERK1/2
and JNK pathways in microglial cells (175). Stimulation of CB2 receptors by 2-AG also
increases microglial cell proliferation (176). However, in the present study we found that
anandamide decreased ganglia survival at high concentration (10uM), and this effect
appeared to be mediated by CB2 receptors; suggesting activation of CB2 receptors could
induce ganglia death. Our data appears to be contradictory to the results mentioned
above. In our primary ganglia system where enteric neurons and enteric glia coexist,
neuron-glia communication is an important factor for mediating ganglia survival. This is
a very different relationship and is different from the studies utilizing the microglial cell
line (176). Another possible reason for the difference could be due to the different
agonists used. Anandamide acts as a partial agonist while 2-AG functions as a full agonist
for CB2. Moreover, the agonistic activity of 2-AG was attenuated by anandamide (177).
Both anandamide (0.036 nmol/g tissue) and 2-AG (44 nmol/g tissue) are found in the gut
(110), and understanding how these two endogenous agonists modulate CB2 receptors
could be important for elucidating the mechanisms of endocannabinoid in gut
inflammatory diseases. It is important to note too that we find different effect of
anandamide depending on the concentration. It is not known whether in physiological or
pathological conditions, the local concentration of anandamide could be up to the 10uM
level necessary to activate CB2 receptors.
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Role of CB2 in enteric neuronal survival
It has been proposed that activation of CB2 receptors is neuroprotective (see review 178).
CB2 receptors were up regulated or inducible after pathological neuroinflammatory
insults and activation of CB2 receptors provided neuroprotection in neurodegenerative
disorders such as Alzheimer’s disease (AD), Huntington’s disease (HD), amyotrophic
lateral sclerosis (ALS) and multiple sclerosis (MS). These effects have been shown to be
mainly through a series of glia-dependent anti-inflammatory actions. For example,
activation of CB2 receptors also reduces the release of proinflammatory factors including
nitric oxide, TNFα, IL-1 and IL-6 in animal models of perinatal hypoxia–ischaemia (179)
and Huntington's disease (180). However, a recent study has shown in vivo and in vitro
that the exogenous cannabinoids delta-9-tetrahydrocannabinol and CP55940 inhibit the
chemotactic response of microglia to Acanthamoeba culbertsoni, an opportunistic
pathogen that is the causative agent of Granulomatous Amoebic Encephalitis, through
activation of the CB2 receptors (181,182). In the present study, we have shown that
AM630 significantly promote the neuronal survival in ganglia by 35% when treatment
together with anandamide (0.1uM) in the presence of glia. AM630 alone tended to
increase neuronal survival in ganglia as well. These data suggest that activation of CB2
receptors could decrease neuronal survival in the presence of glia. Since 0.1uM
anandamide, would be too low to activate CB2 receptors, our data suggests there is an
endogenous tone of endocannabinoids to activate CB2 receptors to decrease the neuronal
survival in the primary cultures of ganglia. This may be mediated by release of
endogenous 2-AG.which is a preferential agonist of the CB2 receptor. This possibility
could be tested in future studies.
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Anandamide inhibits enteric neuronal survival in absence of enteric glia
Anandamide has also been reported to induce cell death in rat cortical neuronal cultures
(134). In addition, Δ9-THC had a neurodegenerative effect in cultured cortical neurons as
well and it appeared to involve the CB1 receptor (133,135). In the present study, we show
that anandamide (1nM-0.1uM) inhibit neuronal survival in the absence of glial cells (i.e.
presence of araC). This effect was partially reversed by CB1 antagonist, AM251 (1uM)
and by the CB2 antagonist AM630. This suggests that the anandamide induced decrease
in neuronal survival without enteric glia cells, could be mediated by both the CB1 and
CB2 receptors. To confirm the direct effect of anandamide on neurons, next we looked at
the newly developed immorto fetal enteric neuronal cell line (IM-FEN). Anandamide
decreased the percentage of neuronal cells in a concentration-dependent manner at both
39 and 33 degree. This further supports the idea that anandamide could inhibit survival of
the neuronal cells.
Anandamide mediated pathways in enteric neuronal cell line
We also found that anandamide increased the expression of phospho-P44/42MAPK in the
enteric neuronal cell line although the lowest concentrations of andamide caused the most
increase in P-MAPK. As the concentration of anandamide increased, the stimulation of
p-MAPK decreased and the percentage of neuronal survival also decreased.

This

suggests that anadamide may have a dual effect on MAPK and that MAPK may have a
protective effect on neuronal suvival. Thus increasing levels of anandamide decrease the
stimulation of p-MAPK leading to decrease protection from cell death. Cannabinoids
mediated MAPK activation has previously been reported in the rat cerebral frontal cortex
(183), the dorsal striatum and the nucleus accumbens (NA) (184) and Neuro2a cells
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(185). A role for cannabinoids-induced apoptosis involved MAPK has also been
demonstrated previously in leukemic cell lines (186) and human breast cancer cells (187).
The previous studies also showed that the tumour suppressor protein, P53 (135), and
Calpain (134) were involved in the cannabinoids-mediated cell death in cultured cortical
neurons. However, whether these were related to MAPK has not been tested yet. Our
studies also demonstrated that anandamide increased levels of p-AKT and that increasing
levels of anandamide led to increased levels of p-AKT. Thus, the levels of p-AKT
paralleled the increased neuronal death as the concentration of anandamide increased.
This pattern is the exact opposite to that described for p-MAPK. Thus, it may be that
rising p-AKT levels and falling p-MAPK levels and or changes in the ratio of these signal
pathways may be the cause of the neuronal cell death caused by increasing levels of
anandamide. This would be an area for future investigations. We should note for
completeness that we also tested the PLC-beta antagonist, U73122. This agent caused a
decrease in the total number of cells (both neural and non-neural cells) in the cultures.
This effect prevented us from examining the role of PLC-beta in these IM-FEN cultures
and we therefore did not examine whether or not anandaminde caused the production of
PLC-beta in these cells. This leaves open the possibility of an additional role of this
signaling pathway in mediating the effects of anandamide.
Role of TRPV1 in myenteric ganglionic survival
It is well known that sensory neurons express TRPV1 receptor. The previous studies have
shown that endocannabinoids stimulate intestinal sensory neurons via the TRPV1 to
release SP, resulting in ileitis in rats (108). In addition, the TRPV1 antagonist
capsazepine (10-5M) inhibited neuropeptide release, including somatostatin, substance P,
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and CGRP, from isolated rat tracheae induced by high concentrations of anandamide (5x
10-5M, 10-4M) (188). However, TRPV1 receptors have not been found in the enteric glia
cell so far. In the present study, we found that both the stimulating and inhibiting effects
of anandamide on ganglionic survival were not inhibited by the TRPV1 antagonist
capsazepine, suggesting TRPV1 receptor may not play a role in anandamide-mediated
ganglia survival. This could be due to the suggestion that TRPV1 was not expressed in
enteric glia and had little effect on enteric glia survival.
Formation of networks in enteric neuronal cell line
Nerves of the enteric nervous system derive from migratory vagal neural crest cells and
sacral neural crest cells, which enter the foregut at embryonic day (E) 9-9.5 in mice and
reach the terminal colon by E14 to E15 (see review 189). The fetal enteric neuronal cell
line (IM-FEN) was isolated from the intestines of E13 immortomice (H-2Kb-tsA58
transgenic mice) fetuses using p75NTR antibody to separate out neural precursor cells
(139). Previous studies have shown that bone morphogenetic protein (BMP) is necessary
for neural crest cell migration and ganglion formation in the enteric nervous system in
chick (190). In the present study we found that this cell line was able to form ganglionlike structures and these structures further interconnected to form complicated networks.
To form this network, the cells need proliferate to 100% confluence so that they can be
very close to each other. This phenomenon can be observed both in 33 and 39 degrees,
suggesting they have this ability even without differentiation in 39 degree. We also
observed that the surrounding cells tended to move toward to the center of ganglionstructure. This implies that there are certain signaling molecules produced by the cells
that act as a chemoattractant to induce this movement. Interestingly, the cells in the core

144

of this structure stain positive for PGP9.5, suggesting that the chemoattractant derives
from the neuronal cells, but not others. This is also supported by our studies in coculture
enteric neuronal cell line with the astrocyte cell line. We found that the astrocyte cell line
alone was not able to form this ganglion-like structure even though they are 100%
confluent, however, the ganglion-like structures and network formed when they were
cocultured together with enteric neuronal cell line. This observation suggest that this
function in vitro could mimic the process of enteric nervous system development in vivo
and could be a good model for studying the ganglia colonization and the mechanisms of
Hirschsprung’s disease. It also suggest that our studies of the effects and mechanims of
action of cannabinoids in the IM-FEN cell line are a good model for the actions of
cannabinoids in the studies of primary ganglia isolated from the guinea pig intestine.
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